Ranibizumab and Bevacizumab for Treatment of Neova Degeneration

Ophthalmology

119, 1388-1398

DOI: 10.1016/j.ophtha.2012.03.053

Citation Report

#	Article	IF	Citations
1	What the comprehensive economics of blindness and visual impairment can help us understand. Indian Journal of Ophthalmology, 2012, 60, 406.	0.5	17
2	Mechanism of Inflammation in Age-Related Macular Degeneration. Mediators of Inflammation, 2012, 2012, 1-16.	1.4	102
3	Anti-VEGF therapies for the treatment of age-related macular degeneration. Journal of Comparative Effectiveness Research, 2012, 1, 485-488.	0.6	1
4	Subtarsal eyelid examination using an oblique slit lamp mirror in cases of eyelid shortening. Eye, 2012, 26, 1386-1388.	1.1	1
5	Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ, The, 2012, 345, e4203-e4203.	3.0	83
6	Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration. British Journal of Ophthalmology, 2012, 96, 1479-1483.	2.1	15
8	Measuring the benefit of 4â€...years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2012, 96, 1469-1473.	2.1	36
9	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 2012, 12, 1299-1313.	1.4	48
11	Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 1563-1571.	1.0	22
12	Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment. Ophthalmology, 2012, 119, 2312-2318.	2.5	342
14	Bevacizumab: as effective as ranibizumab for AMD, but safe?. Reactions Weekly, 2012, &NA;, 5.	0.0	0
15	Mechanisms of Age-Related Macular Degeneration. Neuron, 2012, 75, 26-39.	3.8	756
16	More on a patient-centric approach in the anti-VEGF therapy. Eye, 2012, 26, 1388-1388.	1.1	0
17	Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents. Drugs and Aging, 2012, 29, 949-956.	1.3	28
18	Avastin is as effective as Lucentis for wet AMD and could save NHS Â84m a year, study shows. BMJ, The, 2012, 344, e3275-e3275.	3.0	13
19	Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion. Drugs, 2012, 72, 2063-2071.	4.9	4
21	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, 2012, 119, 2537-2548.	2.5	1,947
22	Comparison of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Injection: Ranibizumab versus Bevacizumab. Journal of Korean Medical Science, 2012, 27, 1580.	1.1	19

#	Article	IF	Citations
23	Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Therapeutics and Clinical Risk Management, 2012, 8, 343.	0.9	15
24	Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration. Journal of Translational Medicine, 2013, 11, 53.	1.8	30
25	Bevacizumab versus ranibizumab: why are we not playing the joker?. International Journal of Clinical Pharmacy, 2013, 35, 507-509.	1.0	7
26	Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucomaâ€"results from a prospective interventional case series. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2403-2413.	1.0	38
27	Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2499-2503.	1.0	20
28	Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 2327-2330.	1.0	3
29	In-vivo investigation of laser-induced choroidal neovascularization in rat using spectral-domain optical coherence tomography (SD-OCT). Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1293-1301.	1.0	15
30	Drug-induced uveitis. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 43.	1.2	64
31	Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration. Drugs and Aging, 2013, 30, 331-358.	1.3	42
32	A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 2630-2636.	2.5	99
35	Current Antiâ€"Vascular Endothelial Growth Factor Dosing Regimens. Ophthalmology, 2013, 120, S3-S7.	2.5	86
36	Incidence of Choroidal Neovascularization inÂthe Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2013, 120, 2035-2041.	2.5	81
37	Stereotactic Radiotherapy for Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 1893-1900.	2.5	63
41	Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet, The, 2013, 382, 1258-1267.	6.3	623
42	Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. British Journal of Ophthalmology, 2013, 97, 1497-1507.	2.1	43
43	Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology, 2013, 155, 429-437.e7.	1.7	313
44	Potential drug interventions for diabetic retinopathy. Drug Discovery Today, 2013, 18, 1334-1341.	3.2	2
45	Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology, 2013, 120, 2300-2309.	2.5	221

#	Article	IF	Citations
46	Mature vessel occlusion after anti-VEGF treatment in a retinal arteriovenous malformation. BMC Ophthalmology, 2013, 13, 60.	0.6	14
47	Serum Levels of Intravitreal Bevacizumab After Vitrectomy, Lensectomy and Non-Surgical Controls. Current Eye Research, 2013, 38, 761-766.	0.7	11
48	Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation. Japanese Journal of Ophthalmology, 2013, 57, 211-220.	0.9	11
49	Neovascular (Exudative or â€œWetâ€) Age-Related Macular Degeneration. , 2013, , 1183-1212.		4
50	Diffusion of macromolecules through sclera. Acta Ophthalmologica, 2013, 91, e1-6.	0.6	19
51	Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. British Journal of Ophthalmology, 2013, 97, 454-459.	2.1	150
52	Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis â€“ implications for cardiovascular safety. International Journal of Cardiology, 2013, 168, 2453-2461.	0.8	86
53	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. Taiwan Journal of Ophthalmology, 2013, 3, 128-133.	0.3	3
54	Influence of the Vitreomacular Interface onÂOutcomes of Ranibizumab Therapy inÂNeovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 2620-2629.	2.5	74
55	Retinal pigment epithelium cells produce VEGF in response to oxidized phospholipids through mechanisms involving ATF4 and protein kinase CK2. Experimental Eye Research, 2013, 116, 177-184.	1.2	25
56	Treatment of age-related macular degeneration. Lancet, The, 2013, 382, 1230-1232.	6.3	24
57	Switching Antiâ€“Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2013, 156, 1-2.e1.	1.7	38
58	Long-term Safety of Ranibizumab in Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, e68-e69.	2.5	0
59	Author reply. Ophthalmology, 2013, 120, e69.	2.5	0
60	Acute Visual Changes in the Elderly. Clinics in Geriatric Medicine, 2013, 29, 165-180.	1.0	4
61	Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors. American Journal of Ophthalmology, 2013, 156, 23-28.e2.	1.7	123
62	Combination Therapy for Neovascular Age-related Macular Degeneration Refractory to Anti-Vascular Endothelial Growth FactorÂAgents. Ophthalmology, 2013, 120, 2029-2034.	2.5	59
63	Retinal Pigment Epithelial Cell Loss Assessed by Fundus Autofluorescence Imaging in Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 334-341.	2.5	43

#	Article	IF	Citations
64	Neuron-Derived Semaphorin 3A Is an Early Inducer of Vascular Permeability in Diabetic Retinopathy via Neuropilin-1. Cell Metabolism, 2013, 18, 505-518.	7.2	118
65	Optical Coherence Tomography Assessment of Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to Geographic Atrophy. Ophthalmology, 2013, 120, 829-836.	2.5	10
66	Conversion to Aflibercept For Chronic Refractory Or Recurrent Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2013, 156, 29-35.e2.	1.7	164
67	Intravitreal injections: a review of the evidence for best practice. Clinical and Experimental Ophthalmology, 2013, 41, 500-507.	1.3	44
68	Age-related eye disease. Maturitas, 2013, 75, 29-33.	1.0	43
69	Bevacizumab vs ranibizumabâ€”an appraisal of the evidence from CATT and IVAN. Eye, 2013, 27, 289-290.	1.1	11
70	Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1901-1907.	1.0	2
71	Targeted Intraceptor Nanoparticle Therapy Reduces Angiogenesis and Fibrosis in Primate and Murine Macular Degeneration. ACS Nano, 2013, 7, 3264-3275.	7.3	83
72	An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2013, 14, 1017-1028.	0.9	37
73	Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Review of Clinical Pharmacology, 2013, 6, 103-113.	1.3	22
74	Aflibercept: Newly Approved for the Treatment of Macular Edema Following Central Retinal Vein Occlusion. Annals of Pharmacotherapy, 2013, 47, 819-827.	0.9	14
75	Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab. American Journal of Ophthalmology, 2013, 156, 15-22.e1.	1.7	217
76	Immunology of age-related macular degeneration. Nature Reviews Immunology, 2013, 13, 438-451.	10.6	515
77	Optical Coherence Tomography in Retinopathy of Prematurity. Clinics in Perinatology, 2013, 40, 271-296.	0.8	59
78	Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 1046-1056.	2.5	432
79	Pharmacotherapy of Age-Related Macular Degeneration. , 2013, , 1213-1255.		5
80	Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON. Ophthalmology, 2013, 120, 2292-2299.	2.5	854
81	Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2013, 120, 1860-1870.	2.5	226

#	Article	IF	Citations
82	Recent Advances in the Management of Neovascular Glaucoma. Seminars in Ophthalmology, 2013, 28, 165-172.	0.8	43
83	Intravitreal Ranibizumab for Pigment Epithelium Detachment With Subfoveal Occult Choroidal Neovascularization: A Prospective 24-Month Case Series. American Journal of Ophthalmology, 2013, 155, 103-108.e2.	1.7	14
84	Age-Related Macular Degeneration Revisited â€“ Piecing the Puzzle: The LXIX Edward Jackson Memorial Lecture. American Journal of Ophthalmology, 2013, 155, 1-35.e13.	1.7	233
85	The incidence and treatment of diabetic macular edema at the University Eye-Clinic Graz for a period of 2 years. Spektrum Der Augenheilkunde, 2013, 27, 234-238.	0.2	0
86	Cortical responses elicited by photovoltaic subretinal prostheses exhibit similarities to visually evoked potentials. Nature Communications, 2013, 4, 1980.	5.8	117
87	Implications of the Comparisons of Age-Related Macular Degeneration Treatments Trials on Clinical Practice. Ophthalmology, 2013, 120, S8-S10.	2.5	5
88	Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Drugs and Therapy Perspectives, 2013, 29, 268-274.	0.3	0
89	VEGF antagonism and age-related macular degeneration: too much of a good thing?. Expert Review of Ophthalmology, 2013, 8, 103-105.	0.3	3
90	Avastin and Lucentis: what do patients know? A prospective questionnaire survey. JRSM Short Reports, 2013, 4, 204253331348414.	0.6	1
91	Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?. Eye, 2013, 27, 56-64.	1.1	40
92	The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. Eye, 2013, 27, 1429-1431.	1.1	34
93	Intravitreal aflibercept for neovascular age-related macular degeneration. Immunotherapy, 2013, 5, 121-130.	1.0	9
94	Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). Eye, 2013, 27, 959-963.	1.1	22
99	Choroidal naevi complicated by choroidal neovascular membrane and outer retinal tubulation. British Journal of Ophthalmology, 2013, 97, 1014-1019.	2.1	34
100	Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development. BioMed Research International, 2013, 2013, 1-8.	0.9	35
101	In vitro induction of protein complexes between bevacizumab, VEGF-A165and heparin: explanation for deposits observed on endothelial veins in monkey eyes. British Journal of Ophthalmology, 2013, 97, 511-517.	2.1	10
102	The MANTA 1-year results: the anti-VEGF debate continues: TableÂ1. British Journal of Ophthalmology, 2013, 97, 248-250.	2.1	11
103	Prevalence of Age-Related Macular Degeneration in Nakuru, Kenya: A Cross-Sectional Population-Based Study. PLoS Medicine, 2013, 10, e1001393.	3.9	20

#	Article	IF	Citations
104	Anti-vascular endothelial growth factor in age-related macular degeneration: Puzzle or a silent beginning!. Indian Journal of Ophthalmology, 2013, 61, 475.	0.5	3
105	Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients. ISRN Ophthalmology, 2013, 2013, 1-6.	1.7	7
106	Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. British Journal of Ophthalmology, 2013, 97, 1161-1167.	2.1	86
107	Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration. Indian Journal of Ophthalmology, 2013, 61, 490.	0.5	6
108	Results of 2â€...years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2013, 97, 617-621.	2.1	49
109	MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT. Retina, 2013, 33, 1735-1762.	1.0	144
110	Asian Age-Related Macular Degeneration. Asia-Pacific Journal of Ophthalmology, 2013, 2, 32-41.	1.3	33
111	CURRENT KNOWLEDGE AND TRENDS IN AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 1487-1502.	1.0	59
112	Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2013, 24, 205-212.	1.3	26
113	Drug-induced uveitis. Current Opinion in Ophthalmology, 2013, 24, 589-597.	1.3	53
114	INTRAVITREAL BEVACIZUMAB IN THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 1828-1835.	1.0	7
115	Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Current Opinion in Ophthalmology, 2013, 24, 197-204.	1.3	12
116	Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open, 2013, 3, e002269.	0.8	101
117	An epidemiological study of neovascular age-related macular degeneration in Germany. Current Medical Research and Opinion, 2013, 29, 1391-1397.	0.9	10
118	In vivo performance of photovoltaic subretinal prosthesis. , 2013, , .		1
119	Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review. PLoS ONE, 2013, 8, e78538.	1.1	95
120	Anti-vascular endothelial growth factor therapy for diabetic macular edema. Therapeutic Advances in Endocrinology and Metabolism, 2013, 4, 151-169.	1.4	145
121	Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4). PLoS ONE, 2013, 8, e72755.	1.1	17

#	Article	IF	Citations
122	What is new in the management of wet age-related macular degeneration?. British Medical Bulletin, 2013, 105, 201-211.	2.7	14
123	Current Choroidal Neovascularization Treatment. Ophthalmologica, 2013, 230, 55-61.	1.0	21
124	Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. British Journal of Ophthalmology, 2013, 97, 1447-1450.	2.1	67
125	Quality of bevacizumab compounded for intravitreal administration. Eye, 2013, 27, 1090-1097.	1.1	38
126	Three-Year Visual Outcome and Injection Frequency of Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2013, 230, 27-33.	1.0	16
127	Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab. Seminars in Ophthalmology, 2013, 28, 355-360.	0.8	10
128	Age-Related Macular Degeneration, Anti-VEGF Therapy, and Ophthalmic Imaging. JAMA Ophthalmology, 2013, 131, 1124.	1.4	6
129	Hydrosilylated Porous Silicon Particles Function as an Intravitreal Drug Delivery System for Daunorubicin. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 493-500.	0.6	29
130	â€˜Proactiveâ€™ versus â€˜reactiveâ€™ anti-VEGF therapies for neovascular age-related macular degeneration: pros and cons. Expert Review of Ophthalmology, 2013, 8, 321-326.	0.3	1
131	Intravitreal aflibercept use in the treatment of macular edema from central retinal vein occlusion. Expert Review of Ophthalmology, 2013, 8, 227-235.	0.3	1
132	Hyperreflective Dots: A New Spectral-Domain Optical Coherence Tomography Entity for Follow-Up and Prognosis in Exudative Age-Related Macular Degeneration. Ophthalmologica, 2013, 229, 32-37.	1.0	168
133	Postprocedural endophthalmitis: a review. Expert Review of Ophthalmology, 2013, 8, 45-62.	0.3	10
134	Long-term results of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in clinical practice. Expert Review of Ophthalmology, 2013, 8, 37-40.	0.3	1
135	To the Editor. Retina, 2013, 33, 1997-1998.	1.0	0
136	INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR, PERFLUOROPROPANE (C3F8), AND RANIBIZUMAB OR PHOTODYNAMIC THERAPY FOR SUBMACULAR HEMORRHAGE SECONDARY TO WET AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 846-853.	1.0	22
137	OPTICAL COHERENCE TOMOGRAPHYâ€“BASED CORRELATION BETWEEN CHOROIDAL THICKNESS AND DRUSEN LOAD IN DRY AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 1005-1010.	1.0	27
138	Reply. Retina, 2013, 33, 1998-1999.	1.0	0
139	Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2013, 24, 190-196.	1.3	59

#	Article	IF	Citations
140	A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clinical Ophthalmology, 2013, 7, 1987.	0.9	28
142	Automated Segmentation of Pathological Cavities in Optical Coherence Tomography Scans. , 2013, 54, 4385.		29
143	Antivascular endothelial growth factor treatments for neovascular ageâ€related macular degeneration save sight, but does everyone get treated?. Medical Journal of Australia, 2013, 198, 260-261.	0.8	4
144	Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions. Clinical Ophthalmology, 2013, 7, 1377.	0.9	9
145	Accessibility as a Conditioning Factor in Treatment for Exudative Age-related Macular Degeneration. European Journal of Ophthalmology, 2013, 23, 857-864.	0.7	10
146	The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab. Scientific World Journal, The, 2013, 2013, 1-7.	0.8	8
147	Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-NaÃ¯ve Eyes. , 2013, 54, 5754.		34
148	High-dose (2.0 mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy. European Journal of Ophthalmology, 2013, 23, 850-856.	0.7	31
149	Functional Characterization and Multimodal Imaging of Treatment-NaÃ¯ve â€œQuiescentâ€•Choroidal Neovascularization. , 2013, 54, 6886.		128
150	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clinical Interventions in Aging, 2013, 8, 467.	1.3	34
151	Aflibercept in wet AMD: specific role and optimal use. Drug Design, Development and Therapy, 2013, 7, 711.	2.0	108
152	Anti VEGF Agents for Age Related Macular Degeneration. , 2013, , .		0
153	Improving patient outcomes: role of the primary care optometrist in the early diagnosis and management of age-related macular degeneration. Clinical Optometry, 0, , 1.	0.4	6
154	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab Injection. Journal of Korean Ophthalmological Society, 2014, 55, 780.	0.0	0
155	Intravitreal Injection of Normal Saline Induces Retinal Degeneration in the C57BL/6J Mouse. Translational Vision Science and Technology, 2014, 3, 3.	1.1	33
156	Response to Aflibercept After Frequent Re-treatment With Bevacizumab or Ranibizumab in Eyes With Neovascular AMD. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 526-533.	0.4	34
157	Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis. PLoS ONE, 2014, 9, e109744.	1.1	23
158	Laser-Based Strategies to Treat Diabetic Macular Edema: History and New Promising Therapies. Journal of Ophthalmology, 2014, 2014, 1-9.	0.6	30

#	Article	IF	Citations
159	Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2014, 2014, 1-6.	0.6	14
160	A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5â€‰mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. Journal of Ophthalmology, 2014, 2014, 1-9.	0.6	22
161	Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs. Journal of Ophthalmology, 2014, 2014, 1-6.	0.6	15
162	Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema. Translational Vision Science and Technology, 2014, 3, 5.	1.1	57
163	Acute sterile endophthalmitis following intravitreal bevacizumab: case series. Clinical Ophthalmology, 2014, 8, 1793.	0.9	15
164	Long-lasting effects of anti-VEGF/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review. Clinical Ophthalmology, 2014, 8, 2529.	0.9	4
165	Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clinical Ophthalmology, 2014, 8, 1383.	0.9	16
166	Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab. Korean Journal of Ophthalmology: KJO, 2014, 28, 32.	0.5	12
167	Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clinical Ophthalmology, 2014, 8, 1611.	0.9	100
168	Serum Ischemia Modified Albumin and Vascular Endothelial Growth Factor Levels following Intravitreal Bevacizumab Injections. European Journal of Ophthalmology, 2014, 24, 570-575.	0.7	3
169	Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 63-72.	1.2	2
170	Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity. Korean Journal of Ophthalmology: KJO, 2014, 28, 466.	0.5	2
171	Ranibizumab for the treatment of degenerative ocular conditions. Clinical Ophthalmology, 2014, 8, 1187.	0.9	17
172	Quantifying Disrupted Outer Retinal-Subretinal Layer in SD-OCT Images in Choroidal Neovascularization. , 2014, 55, 2329.		26
173	Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come. Neonatology, 2014, 106, 254-260.	0.9	20
174	Aflibercept for diabetic macular edema. Expert Review of Ophthalmology, 2014, 9, 263-268.	0.3	0
175	Hypoxia-Inducible Factor (HIF)/Vascular Endothelial Growth Factor (VEGF) Signaling in the Retina. Advances in Experimental Medicine and Biology, 2014, 801, 275-281.	0.8	74
176	Adverse Events with Biomedicines. , 2014, , .		5

#	Article	IF	Citations
177	Drugs Used in Ocular Treatment. Side Effects of Drugs Annual, 2014, 36, 707-716.	0.6	0
178	Analytical platforms in vitreoretinal proteomics. Bioanalysis, 2014, 6, 3051-3066.	0.6	24
179	Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Expert Opinion on Biological Therapy, 2014, 14, 1837-1848.	1.4	12
180	Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. British Journal of Ophthalmology, 2014, 98, i11-i16.	2.1	102
181	Introduction. British Journal of Ophthalmology, 2014, 98, i1-i2.	2.1	1
182	The Ethics Of â€˜Fail Firstâ€™: Guidelines And Practical Scenarios For Step Therapy Coverage Policies. Health Affairs, 2014, 33, 1779-1785.	2.5	24
183	Lateral and axial measurement differences between spectral-domain optical coherence tomography systems. Journal of Biomedical Optics, 2014, 19, 016014.	1.4	26
184	Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration. BioMed Research International, 2014, 2014, 1-7.	0.9	44
185	What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?. British Journal of Ophthalmology, 2014, 98, i7-i10.	2.1	65
186	Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British Journal of Ophthalmology, 2014, 98, 1192-1196.	2.1	61
187	Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). British Journal of Ophthalmology, 2014, 98, 951-955.	2.1	78
188	The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open, 2014, 4, e005244-e005244.	0.8	31
189	How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration?. Eye, 2014, 28, 832-837.	1.1	25
190	Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. BMJ Open, 2014, 4, e005292-e005292.	0.8	26
191	Treatment patterns of anti-vascular endothelial growth factor (VEGF) and laser therapy among patients with diabetic macular edema (DME). Value in Health, 2014, 17, A260-A261.	0.1	0
192	Antiâ€vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. British Journal of Clinical Pharmacology, 2014, 78, 699-706.	1.1	36
193	Outer Retinal Tubulation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology, 2014, 121, 2423-2431.	2.5	53
194	Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients. Canadian Journal of Ophthalmology, 2014, 49, e146-e148.	0.4	0

#	Article	IF	Citations
195	Detection of Antiranibizumab Antibodies among Patients with Exudative Age-Related Macular Degeneration. Ophthalmologica, 2014, 232, 53-56.	1.0	9
196	Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 234-239.	0.7	17
197	Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Progress in Retinal and Eye Research, 2014, 43, 17-75.	7.3	338
198	Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology, 2014, 132, 915.	1.4	87
199	Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison. Ophthalmologica, 2014, 232, 149-155.	1.0	8
200	Cardiac Issues of Noncardiac Drugs: The Rising Story of Avastin in Age-Related Macular Degeneration. Ophthalmologica, 2014, 231, 75-79.	1.0	8
201	FcÎ³ Receptor Upregulation Is Associated With Immune Complex Inflammation in the Mouse Retina and Early Age-Related Macular Degeneration. , 2014, 55, 247.		38
202	Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye, 2014, 28, 17-22.	1.1	10
203	Bispecific therapeutics for ophthalmic indications: target selection and the optimal molecular format. Expert Review of Ophthalmology, 2014, 9, 217-225.	0.3	5
204	NO CASES OF ENDOPHTHALMITIS AFTER 20,293 INTRAVITREAL INJECTIONS IN AN OPERATING ROOM SETTING. Retina, 2014, 34, 951-957.	1.0	54
205	Intravitreal Bevacizumab in Retinopathy of Prematurity. Asia-Pacific Journal of Ophthalmology, 2014, 3, 368-378.	1.3	10
206	INCIDENCE OF PRESUMED ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION PERFORMED IN THE OPERATING ROOM. Retina, 2014, 34, 12-17.	1.0	57
207	Bevacizumab and Diabetic Vitrectomy. International Ophthalmology Clinics, 2014, 54, 111-126.	0.3	1
208	POOR RESPONDERS TO BEVACIZUMAB PHARMACOTHERAPY IN AGE-RELATED MACULAR DEGENERATION AND IN DIABETIC MACULAR EDEMA DEMONSTRATE INCREASED RISK FOR OBSTRUCTIVE SLEEP APNEA. Retina, 2014, 34, 2423-2430.	1.0	40
209	EXACERBATION OF CHOROIDAL AND RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2014, 34, 1308-1315.	1.0	67
210	Trends in Age-Related Macular Degeneration Management in Singapore. Optometry and Vision Science, 2014, 91, 872-877.	0.6	13
211	Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2014, 25, 158-163.	1.3	30
212	ANTI-VEGF TREATMENT IN NEOVASCULAR AGEâ€“RELATED MACULAR DEGENERATION. Retina, 2014, 34, 1531-1538.	1.0	115

#	Article	IF	Citations
213	SENSITIVITY OF FLUID DETECTION IN PATIENTS WITH NEOVASCULAR AMD USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY HIGH-DEFINITION LINE SCANS. Retina, 2014, 34, 1163-1166.	1.0	17
214	Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open, 2014, 4, e005094-e005094.	0.8	66
215	INTRAVITREAL INJECTION TECHNIQUE AND MONITORING. Retina, 2014, 34, S1-S18.	1.0	221
216	ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS. Retina, 2014, 34, 18-23.	1.0	74
217	TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2014, 34, 846-852.	1.0	24
218	The link between intravitreal antivascular endothelial growth factor injections and glaucoma. Current Opinion in Ophthalmology, 2014, 25, 127-133.	1.3	32
219	INTRAOCULAR PRESSURE IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SWITCHED TO AFLIBERCEPT INJECTION AFTER PREVIOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENTS. Retina, 2014, 34, 2161-2166.	1.0	24
220	OUTCOMES OF ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL OSTEOMA. Retina, 2014, 34, 1750-1756.	1.0	29
221	Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study. Cutaneous and Ocular Toxicology, 2014, 33, 275-282.	0.5	8
222	Present and Possible Therapies for Age-Related Macular Degeneration. ISRN Ophthalmology, 2014, 2014, 1-7.	1.7	22
223	Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies. JAMA Ophthalmology, 2014, 132, 1317.	1.4	108
224	VEGFAandVEGFR2Gene Polymorphisms and Response to Antiâ€“Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmology, 2014, 132, 521.	1.4	53
225	Drugs for Macular Degeneration, Price Discrimination, and Medicareâ€™s Responsibility Not to Overpay. JAMA - Journal of the American Medical Association, 2014, 312, 23.	3.8	12
226	Drugs for Macular Degenerationâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 312, 2045.	3.8	2
227	Two-Year Outcome after Combination Therapy for Polypoidal Choroidal Vasculopathy: Comparison with Photodynamic Monotherapy and Anti-Vascular Endothelial Growth Factor Monotherapy. Ophthalmologica, 2014, 231, 86-93.	1.0	20
228	Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2014, 231, 80-85.	1.0	9
231	RESULTS OF INTRAVITREAL RANIBIZUMAB WITH A PRN REGIMEN IN THE TREATMENT OF EXTRAFOVEAL AND JUXTAFOVEAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATION. Retina, 2014, 34, 860-867.	1.0	8
232	Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye, 2014, 28, 538-545.	1.1	75

#	Article	IF	Citations
233	Ocular Disease due to Toxoplasma gondii. , 2014, , 161-192.		2
235	Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy. FEBS Letters, 2014, 588, 1365-1371.	1.3	23
236	Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 157, 825-833.e1.	1.7	77
237	Landmark matching based retinal image alignment by enforcing sparsity in correspondence matrix. Medical Image Analysis, 2014, 18, 903-913.	7.0	32
238	Comparison of Outcomes from a Phase 3 Study of Age-Related Macular Degeneration with a Matched, Observational Cohort. Ophthalmology, 2014, 121, 676-681.	2.5	41
239	Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration. Ophthalmology, 2014, 121, 188-192.	2.5	127
240	Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration â€" monthly injections versus pro re nata. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 31-34.	1.0	27
241	Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 889-897.	1.0	15
242	Pathologic Myopia. , 2014, , .		41
243	Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Current Ophthalmology Reports, 2014, 2, 1-5.	0.5	22
244	Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. Current Ophthalmology Reports, 2014, 2, 6-13.	0.5	5
245	Management Paradigms for Diabetic Macular Edema. American Journal of Ophthalmology, 2014, 157, 505-513.e8.	1.7	89
246	Drugs used in ocular treatment. Side Effects of Drugs Annual, 2014, , 873-887.	0.6	0
247	Restoring Visual Function to Blind Mice with a Photoswitch that Exploits Electrophysiological Remodeling of Retinal Ganglion Cells. Neuron, 2014, 81, 800-813.	3.8	165
249	The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1911-1920.	1.0	50
250	Angiopoietin-1 Suppresses Choroidal Neovascularization and Vascular Leakage. , 2014, 55, 2191.		51
251	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. Expert Review of Clinical Pharmacology, 2014, 7, 375-391.	1.3	21
252	Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Survey of Ophthalmology, 2014, 59, 1-18.	1.7	122

#	Article	IF	Citations
253	The ABCs of RVO: A review of retinal venous occlusion. Australasian journal of optometry, The, 2014, 97, 311-323.	0.6	34
254	Anti-vascular endothelial growth factor for diabetic macular oedema. , 2014, , CD007419.		113
255	Omega-3 Supplementation Combined With Antiâ€“Vascular Endothelial Growth Factor Lowers Vitreal Levels of Vascular Endothelial Growth Factor in Wet Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 158, 1071-1078.e1.	1.7	30
256	Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway. Seminars in Ophthalmology, 2014, 29, 263-275.	0.8	9
257	Complications of Subspecialty Ophthalmic Care: Endophthalmitis after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Medications. Seminars in Ophthalmology, 2014, 29, 257-262.	0.8	26
258	Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema. Ophthalmology, 2014, 121, 2237-2246.	2.5	29
259	Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 2193-2203.e7.	2.5	64
260	Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review. Eye, 2014, 28, 1399-1406.	1.1	20
261	A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema. Ophthalmology, 2014, 121, 2473-2481.	2.5	270
262	Injection frequency and anatomic outcomes 1â€…year following conversion to aflibercept in patients with neovascular age-related macular degeneration. British Journal of Ophthalmology, 2014, 98, 1205-1207.	2.1	44
263	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. , 2014, , CD011230.		106
264	Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology, 2014, 98, 1636-1641.	2.1	302
265	Emerging treatments for wet age-related macular degeneration. Expert Opinion on Emerging Drugs, 2014, 19, 157-164.	1.0	43
266	Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 346-352.	0.6	20
267	Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 2181-2192.	2.5	377
268	Can they make a complaint against me if I have a complication on administering bebacizumab (AvastinÂ®)?. Archivos De La Sociedad Espanola De Oftalmologia, 2014, 89, 173-174.	0.1	0
269	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. Expert Opinion on Drug Safety, 2014, 13, 1259-1270.	1.0	13
270	The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 158, 769-779.e2.	1.7	167

#	Article	IF	Citations
271	Adverse Gastrointestinal Events with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Nested Caseâ€“Control Study. Drug Safety, 2014, 37, 723-733.	1.4	5
272	IV.E. Principles and Practice of Intravitreal Application of Drugs. , 2014, , 509-521.		4
273	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane Library, 2014, , CD005139.	1.5	255
274	Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift, 2014, 126, 355-359.	1.0	7
275	Intravitreal vascular endothelial growth factor. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 583-588.	1.0	2
276	Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1705-1709.	1.0	68
277	Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1573-1579.	1.0	15
278	Calculating the predicted retinal thickness from spectral domain and time domain optical coherence tomography â€“ comparison of different methods. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1491-1499.	1.0	10
280	Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks. American Journal of Ophthalmology, 2014, 157, 374-377.e2.	1.7	25
281	Ocular delivery of macromolecules. Journal of Controlled Release, 2014, 190, 172-181.	4.8	201
282	Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opinion on Drug Delivery, 2014, 11, 1647-1660.	2.4	108
283	Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor A. Molecular Pharmaceutics, 2014, 11, 3421-3430.	2.3	73
284	Pharmacokinetics, Electrophysiological, and Morphological Effects of the Intravitreal Injection of Mycophenolic Acid in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 502-511.	0.6	8
285	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology, 2014, 98, 1144-1167.	2.1	463
288	The Neovascular Age-Related Macular Degeneration Database. Ophthalmology, 2014, 121, 1966-1975.	2.5	141
289	Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Survey of Ophthalmology, 2014, 59, 134-165.	1.7	93
290	Comparison of Optical Coherence Tomography Assessments in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2014, 121, 1956-1965.e2.	2.5	34
291	The Neovascular Age-Related Macular Degeneration Database: Multicenter Study ofÂ92â€‰976 Ranibizumab Injections. Ophthalmology, 2014, 121, 1092-1101.	2.5	317

#	Article	IF	Citations
292	Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration. Ophthalmology, 2014, 121, 936-945.	2.5	71
293	Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 1740-1747.	2.5	148
294	Impact of Vitreomacular Adhesion on Ranibizumab Mono- and Combination Therapy for Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 158, 328-336.e1.	1.7	35
295	Choroidal Neovascularization Associated With Focal Choroidal Excavation. American Journal of Ophthalmology, 2014, 157, 710-718.e1.	1.7	50
296	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. Ophthalmology, 2014, 121, 193-201.	2.5	693
297	Intravitreal Anti-Vascular Endothelial Growth Factor for Submacular Hemorrhage from Choroidal Neovascularization. Ophthalmology, 2014, 121, 926-935.	2.5	69
299	Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 1237-1245.	2.5	146
300	Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2014, 121, 150-161.	2.5	483
301	Sporadic Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). American Journal of Ophthalmology, 2014, 158, 128-135.e10.	1.7	16
302	Anti-angiogenic effect of the basement membrane protein nidogen-1 in a mouse model of choroidal neovascularization. Experimental Eye Research, 2014, 118, 80-88.	1.2	12
303	Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. British Journal of Ophthalmology, 2014, 98, 1197-1200.	2.1	15
304	Switching To Less Expensive Blindness Drug Could Save Medicare Part B $18ÂBillion Over A Ten-Year Period. Health Affairs, 2014, 33, 931-939.	2.5	72
305	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opinion on Drug Safety, 2014, 13, 1-18.	1.0	44
306	Radial Versus Raster Spectral-Domain Optical Coherence Tomography Scan Patterns for Detection of Macular Pathology. American Journal of Ophthalmology, 2014, 158, 345-353.e2.	1.7	21
307	A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. British Journal of Ophthalmology, 2014, 98, i22-i27.	2.1	64
308	Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Canadian Journal of Ophthalmology, 2014, 49, 261-266.	0.4	39
309	Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. American Journal of Ophthalmology, 2014, 158, 537-543.e2.	1.7	55
310	The Sustained Delivery of Resveratrol or a Defined Grape Powder Inhibits New Blood Vessel Formation in a Mouse Model of Choroidal Neovascularization. Molecules, 2014, 19, 17578-17603.	1.7	18

#	Article	IF	Citations
311	Retinal and Choroidal Thickness Changes after Single Anti-VEGF Injection in Neovascular Age-related Macular Degeneration: Ranibizumab vs Bevacizumab. European Journal of Ophthalmology, 2014, 24, 904-910.	0.7	20
312	Cost-Effectiveness of Treatment of Diabetic Macular Edema. Annals of Internal Medicine, 2014, 160, 18-29.	2.0	61
314	EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES. Retina, 2014, 34, 188-195.	1.0	104
315	ASSESSMENT OF THE RISK OF NEEDLESTICK INJURIES ASSOCIATED WITH INTRAVITREAL INJECTIONS. Retina, 2014, 34, 781-784.	1.0	8
316	Stereotactic low voltage x-ray radiotherapy for treating neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2014, 9, 153-158.	0.3	0
317	Choose the right treatment for the right patients. Taiwan Journal of Ophthalmology, 2015, 5, 147-148.	0.3	0
318	Neovascular Age-Related Macular Degeneration. Developments in Ophthalmology, 2016, 55, 125-136.	0.1	52
319	Choroidal Neovascularization Secondary to Myopia, Infection and Inflammation. Developments in Ophthalmology, 2016, 55, 167-175.	0.1	30
320	Translational public health care perspective: Intravitreal treatment of neovascular ageâ€related macular degeneration has revolutionized clinical ophthalmology. Acta Ophthalmologica, 2015, 93, 103-104.	0.6	6
321	Platelet-Derived Growth Factor Inhibitors: A Potential Therapeutic Approach for Ocular Neovascularization. Developments in Ophthalmology, 2016, 55, 310-316.	0.1	27
322	Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab. Developments in Ophthalmology, 2016, 55, 246-251.	0.1	7
323	Ocular Infection: Endophthalmitis. Developments in Ophthalmology, 2016, 55, 176-188.	0.1	33
324	Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab. Developments in Ophthalmology, 2016, 55, 232-245.	0.1	20
325	Combined therapy in diabetic macular edema. Medicina Universitaria, 2015, 17, 153-157.	0.1	1
326	Chapter 4: Age-related Macular Degeneration. , 2015, , 33-42.		0
327	Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. British Journal of Ophthalmology, 2015, 99, 1268-1270.	2.1	16
328	Evolving Knowledge in Pharmacologic Treatments of Age-Related Macular Degeneration. Developments in Ophthalmology, 2016, 55, 1-6.	0.1	0
329	Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell. Acta Ophthalmologica, 2015, 93, e631-43.	0.6	18

#	Article	IF	Citations
330	Visual outcomes in relation to time to treatment in neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2015, 93, 616-620.	0.6	43
331	Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuityâ€‰â‰¥â€‰0.05. BMC Ophthalmology, 2015, 15, 138.	0.6	1
332	Early detection of age related macular degeneration: current status. International Journal of Retina and Vitreous, 2015, 1, 20.	0.9	44
333	Finding the Optimal Treatment Plan for Exudative AMD. International Ophthalmology Clinics, 2015, 55, 103-112.	0.3	4
334	OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TIME COURSE OF CHOROIDAL NEOVASCULARIZATION IN RESPONSE TO ANTI-ANGIOGENIC TREATMENT. Retina, 2015, 35, 2260-2264.	1.0	125
335	INCIDENCE OF OUTER RETINAL TUBULATION IN RANIBIZUMAB-TREATED AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1166-1172.	1.0	16
336	COMPARISON OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS AND CLINICAL REVIEW STRATEGIES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1315-1322.	1.0	7
337	INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1992-2000.	1.0	5
338	INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. Retina, 2015, 35, 2450-2456.	1.0	55
339	Ocular inflammation associated with antivascular endothelial growth factor treatment. Current Opinion in Ophthalmology, 2015, 26, 184-187.	1.3	15
340	To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving antiâ€vascular endothelial growth factor treatment for neovascular ageâ€related macular degeneration?. Clinical and Experimental Ophthalmology, 2015, 43, 707-710.	1.3	6
341	Predictability of Recalcitrance in Neovascular Age-Related Macular Degeneration With Indocyanine Green Angiography. Asia-Pacific Journal of Ophthalmology, 2015, 4, 187-190.	1.3	2
342	CHANGES OF CHOROIDAL NEOVASCULARIZATION IN INDOCYANINE GREEN ANGIOGRAPHY AFTER INTRAVITREAL RANIBIZUMAB INJECTION. Retina, 2015, 35, 999-1006.	1.0	4
343	TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY. Retina, 2015, 35, 1547-1554.	1.0	15
344	ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1957-1963.	1.0	18
345	Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2015, 26, 200-205.	1.3	0
346	Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice. Chinese Medical Journal, 2015, 128, 1154-1159.	0.9	10
347	Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. Clinical Ophthalmology, 2015, 9, 959.	0.9	7

#	Article	IF	Citations
348	Visual Function and Its Relationship with Severity of Early, and Activity of Neovascular, Age-Related Macular Degeneration. Journal of Clinical & Experimental Ophthalmology, 2015, 06, 488.	0.1	1
349	Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value. , 2015, 56, 4129.		37
350	Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration. Clinical Ophthalmology, 2015, 9, 1315.	0.9	10
351	Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Korean Journal of Ophthalmology: KJO, 2015, 29, 226.	0.5	25
352	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clinical Ophthalmology, 2015, 9, 1759.	0.9	28
353	One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK. Clinical Ophthalmology, 2015, 9, 1779.	0.9	15
354	Switching Intravitreal anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2015, 25, 51-56.	0.7	10
355	Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. Korean Journal of Ophthalmology: KJO, 2015, 29, 315.	0.5	14
356	Systemic Counterregulatory Response of Placental Growth Factor Levels to Intravitreal Aflibercept Therapy. , 2015, 56, 3279.		17
357	Treatment Patterns of Anti-Vascular Endothelial Growth Factor and Laser Therapy Among Patients with Diabetic Macular Edema. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 735-741.	0.5	13
358	Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor. Clinical Ophthalmology, 2015, 9, 1651.	0.9	0
359	Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives. Clinical Ophthalmology, 2015, 9, 1829.	0.9	10
360	Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration. International Journal of Molecular Sciences, 2015, 16, 19796-19811.	1.8	5
361	Age-Related Macular Degeneration: Advances in Management and Diagnosis. Journal of Clinical Medicine, 2015, 4, 343-359.	1.0	107
362	Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?. Journal of Clinical Medicine, 2015, 4, 1079-1101.	1.0	26
363	Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 2015, 4, 1380-1402.	1.0	56
364	22 antiâ€“vascular endothelial growth factor (anti-VEGF) therapyOptical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. , 2015, , .		0
365	Current perspectives on ranibizumab. Clinical Ophthalmology, 2015, 9, 533.	0.9	15

#	Article	IF	Citations
366	Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. , 2015, 56, 5040.		46
367	Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2015, 9, 5397.	2.0	55
368	Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clinical Ophthalmology, 2015, 9, 2355.	0.9	39
369	Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clinical Ophthalmology, 2015, 9, 1001.	0.9	35
370	Relationship of Retinal Morphology and Retinal Sensitivity in the Treatment of Neovascular Age-Related Macular Degeneration Using Aflibercept. Investigative Ophthalmology and Visual Science, 2015, 56, 1158-1167.	3.3	28
371	Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0137866.	1.1	20
372	Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System. PLoS ONE, 2015, 10, e0139556.	1.1	5
373	Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Frontiers in Pharmacology, 2015, 6, 248.	1.6	73
374	Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2015, 29, 396.	0.5	5
375	Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Design, Development and Therapy, 2015, 9, 2311.	2.0	66
376	Gene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy. Journal of Ophthalmology, 2015, 2015, 1-12.	0.6	16
377	Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. Journal of Ophthalmology, 2015, 2015, 1-5.	0.6	8
378	Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis. Journal of Ophthalmology, 2015, 2015, 1-8.	0.6	8
379	Management of Diabetic Retinopathy and Other Ocular Complications in Type 1 Diabetes. , 2015, , .		2
380	EFFECT OF RANIBIZUMAB ON HIGH-SPEED INDOCYANINE GREEN ANGIOGRAPHY AND MINIMUM INTENSITY PROJECTION OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 58-68.	1.0	2
381	Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clinical Ophthalmology, 2015, 9, 773.	0.9	44
382	Intravitreal administration of bevacizumab: pros and cons. DARU, Journal of Pharmaceutical Sciences, 2015, 23, 27.	0.9	3
384	The genetics of age-related macular degeneration (AMD) â€“ Novel targets for designing treatment options?. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 194-202.	2.0	33

#	Article	IF	Citations
385	Prospective Evaluation of Teleophthalmology in Screening and Recurrence Monitoring of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2015, 133, 276.	1.4	59
386	Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child. Eye, 2015, 29, 569-573.	1.1	5
387	Randomizing 1 Eye or 2 Eyes. JAMA Ophthalmology, 2015, 133, 9.	1.4	18
388	Structures affecting recovery of macular function in patients with age-related macular degeneration after intravitreal ranibizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1201-1209.	1.0	5
389	Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Antiâ€"Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 803-808.	2.5	112
390	Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2015, 99, 1341-1344.	2.1	33
391	The Effect of Multiple Injections of Ranibizumab on Retinal Nerve Fiber Layer Thickness in Patients with Age-Related Macular Degeneration. Current Eye Research, 2015, 40, 87-92.	0.7	32
392	Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: â€œreal lifeâ€•long-term outcome. BMC Ophthalmology, 2015, 15, 39.	0.6	9
393	Two-Year Outcomes of â€œTreat and Extendâ€•Intravitreal Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1212-1219.	2.5	148
394	Comparative Effectiveness of Bevacizumab and Ranibizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology, 2015, 133, 363.	1.4	2
395	The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development. Journal of Pharmaceutical Sciences, 2015, 104, 3330-3342.	1.6	59
396	DÃ©gÃ©nÃ©rescence maculaire liÃ©e Ã â€™Ã¢ge. Ã‰tat des lieux 2015. Revue Francophone D'Orthoptie, 2015, 8, 118-135.	0.0	1
397	A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation. Saudi Journal of Ophthalmology, 2015, 29, 147-155.	0.3	5
398	Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Reports in Ophthalmology, 2015, 6, 44-50.	0.3	25
399	Peripapillary Choroidal Neovascularization Associated with Optic Nerve Head Drusen Treated with Anti-VEGF Agents. Case Reports in Ophthalmology, 2015, 6, 51-55.	0.3	10
400	Systemic safety of anti-VEGF drugs: a commentary. Expert Opinion on Drug Safety, 2015, 14, 379-388.	1.0	20
401	Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 138-145.	2.5	38
402	Risk Factors for Geographic Atrophy After Intravitreal Ranibizumab Injections for Retinal Angiomatous Proliferation. American Journal of Ophthalmology, 2015, 159, 285-292.e1.	1.7	91

#	Article	IF	Citations
403	Current choice of treatments for neovascular AMD. Expert Review of Clinical Pharmacology, 2015, 8, 135-140.	1.3	26
404	Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 579-588.	2.5	57
405	Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily withÂRanibizumab. Ophthalmology, 2015, 122, 589-594.e1.	2.5	25
406	Optical Coherence Tomography, Fluorescein Angiography, and the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 222-223.	2.5	9
407	Incidence of Myocardial Infarction, Stroke, and Death in Patients With Age-Related Macular Degeneration Treated With Intravitreal Antiâ€"Vascular Endothelial Growth Factor Therapy. American Journal of Ophthalmology, 2015, 159, 557-564.e1.	1.7	27
408	Quercetin alleviates 4-hydroxynonenal-induced cytotoxicity and inflammation in ARPE-19 cells. Experimental Eye Research, 2015, 132, 208-215.	1.2	44
409	Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with ageâ€related macular degeneration: a randomised, prospective trial. Acta Ophthalmologica, 2015, 93, e154-9.	0.6	76
410	Antiâ€"Vascular Endothelial Growth Factor WithÂor Without Pneumatic Displacement forÂSubmacular Hemorrhage. American Journal of Ophthalmology, 2015, 159, 904-914.e1.	1.7	39
412	Pigment Epithelial Detachment Followed byÂRetinal Cystoid Degeneration Leads toÂVision Loss in Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 822-832.	2.5	170
413	Safety, sterility and stability of directâ€fromâ€vial multiple dosing intravitreal injection of bevacizumab. Clinical and Experimental Ophthalmology, 2015, 43, 466-473.	1.3	18
414	Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017178-a017178.	2.9	53
415	Therapies for Macular Edema Associated withÂCentral Retinal Vein Occlusion. Ophthalmology, 2015, 122, 769-778.	2.5	75
416	Management of pseudophakic cystoid macular edema. Survey of Ophthalmology, 2015, 60, 123-137.	1.7	88
417	Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye, 2015, 29, 561-568.	1.1	38
418	Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration. Drug Safety, 2015, 38, 279-293.	1.4	20
419	Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1217-1225.	1.0	32
420	Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Japanese Journal of Ophthalmology, 2015, 59, 36-42.	0.9	25
421	Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 271-278.	2.0	96

#	Article	IF	Citations
422	Antibody therapies and their challenges in the treatment of age-related macular degeneration. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 158-172.	2.0	54
424	Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1211-1216.	1.0	28
425	Nanoparticles for the treatment of ocular neovascularizations. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 294-306.	2.0	31
426	A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS ONE, 2015, 10, e0129383.	1.1	69
427	All That Glitters Are Not Flecks: Inflammatory Choroidal Neovascularization in Fundus Flavimaculatus. Ocular Immunology and Inflammation, 2015, 23, 188-190.	1.0	4
428	Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. American Journal of Ophthalmology, 2015, 160, 345-353.e5.	1.7	49
429	Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Saudi Journal of Ophthalmology, 2015, 29, 287-291.	0.3	25
430	Targeting the Effect of VEGF in Diabetic Macular Edema. New England Journal of Medicine, 2015, 373, 479-482.	13.9	6
431	Routine versus As-Needed Bevacizumab withÂ12-Weekly Assessment Intervals forÂNeovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1348-1355.	2.5	11
432	Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2015, 122, 1846-1853.e5.	2.5	144
433	Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice. Ophthalmologica, 2015, 233, 155-161.	1.0	46
434	Stratified Sampling Voxel Classification for Segmentation of Intraretinal and Subretinal Fluid in Longitudinal Clinical OCT Data. IEEE Transactions on Medical Imaging, 2015, 34, 1616-1623.	5.4	77
435	Antibody-Drug Conjugate (ADC) Research in Ophthalmologyâ€"a Review. Pharmaceutical Research, 2015, 32, 3572-3576.	1.7	5
436	Long-Term Outcomes of Treatment ofÂNeovascular Age-Related MacularÂDegeneration. Ophthalmology, 2015, 122, 1837-1845.	2.5	206
437	Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice. Molecular Pharmacology, 2015, 88, 316-325.	1.0	39
438	Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology, 2015, 99, 220-226.	2.1	474
439	Attacks on publicly funded trials: what happens when industry does not want to know the answer. BMJ, The, 2015, 350, h1701-h1701.	3.0	3
440	Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2015, 16, 1769-1781.	0.9	27

#	Article	IF	Citations
441	Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. Expert Opinion on Biological Therapy, 2015, 15, 1349-1358.	1.4	20
442	A sustained intravitreal drug delivery system with remote real time monitoring capability. Acta Biomaterialia, 2015, 24, 309-321.	4.1	12
443	The Effects of the Frequency of the Initial Treatment with Intravitreal Bevacizumab on Macular Volume and Visual Acuity. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 277-281.	0.6	2
444	Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye, 2015, 29, 820-827.	1.1	31
445	Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology, 2015, 133, 726.	1.4	2
446	Clinical Outcomes in the First Two Years of Femtosecond Laserâ€“Assisted Cataract Surgery. American Journal of Ophthalmology, 2015, 160, 396-397.	1.7	2
447	Postinjection Endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology, 2015, 122, 817-821.	2.5	73
448	Stem cell based therapies for age-related macular degeneration: The promises and the challenges. Progress in Retinal and Eye Research, 2015, 48, 1-39.	7.3	167
449	Myopic choroidal neovascularisation: current concepts and update on clinical management. British Journal of Ophthalmology, 2015, 99, 289-296.	2.1	135
450	Optical Coherence Tomography Angiography Signs of Vascular Abnormalization With Antiangiogenic Therapy for Choroidal Neovascularization. American Journal of Ophthalmology, 2015, 160, 6-16.	1.7	261
452	Macular Atrophy Progression and 7-Year Vision Outcomes in Subjects From the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Studyâ^—. American Journal of Ophthalmology, 2015, 159, 915-924.e2.	1.7	168
454	The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1479-1483.	1.0	3
455	A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1867-1872.	1.0	19
456	Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2015, 59, 173-178.	0.9	5
457	Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy. BMC Ophthalmology, 2015, 15, 37.	0.6	7
458	Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial. Trials, 2015, 16, 85.	0.7	7
459	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. New England Journal of Medicine, 2015, 372, 1193-1203.	13.9	1,255
460	Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. British Journal of Ophthalmology, 2015, 99, 359-364.	2.1	18

#	Article	IF	Citations
461	A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab. British Journal of Ophthalmology, 2015, 99, 1554-1559.	2.1	20
462	The Expanding Role of Therapeutic Antibodies. International Reviews of Immunology, 2015, 34, 202-264.	1.5	22
463	Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. Ophthalmologica, 2015, 233, 169-175.	1.0	57
464	GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 176-186.	1.0	98
465	FREQUENCY AND CHARACTERISTICS OF INTRAOCULAR INFLAMMATION AFTER AFLIBERCEPT INJECTION. Retina, 2015, 35, 681-686.	1.0	27
466	STEREOTACTIC RADIOTHERAPY FOR WET AGE-RELATED MACULAR DEGENERATION (INTREPID). Retina, 2015, 35, 194-204.	1.0	18
467	PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 381-391.	1.0	31
468	BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 187-193.	1.0	31
469	Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison ofÂAge-Related Macular Degeneration Treatments Trials. Ophthalmology, 2015, 122, 1203-1211.	2.5	48
470	Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2015, 122, 809-816.	2.5	186
471	Drug-loaded nanocarriers for back-of-the-eye diseases- formulation limitations. Journal of Drug Delivery Science and Technology, 2015, 30, 331-341.	1.4	12
472	Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. BMJ Open, 2015, 5, e008405.	0.8	23
473	Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology, 2015, 122, 2523-2531.e1.	2.5	84
474	Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye, 2015, 29, S1-S11.	1.1	22
475	Long-Term Follow-Up of Choroidal Neovascularization in Pathological Myopia Treated with Intravitreal Ranibizumab. Klinische Monatsblatter Fur Augenheilkunde, 2015, 232, 542-547.	0.3	12
476	Endophthalmitis Outbreak Associated with Repackaged Bevacizumab. Emerging Infectious Diseases, 2015, 21, 171-173.	2.0	31
477	Treatment of wet ageâ€related macular degeneration by ranibizumab in â€œreal lifeâ€•in France: treatment behaviours and associated visual outcome. Acta Ophthalmologica, 2015, 93, e179-80.	0.6	2
478	A prospective, observational, openâ€label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2015, 93, 126-133.	0.6	27

#	Article	IF	Citations
479	Association of Compounded Bevacizumab With Postinjection Endophthalmitis. JAMA Ophthalmology, 2015, 133, 1159.	1.4	51
480	New add-on intraocular lens for patients with age-related macular degeneration. Journal of Cataract and Refractive Surgery, 2015, 41, 1559-1563.	0.7	37
482	Functional and Anatomic Efficacy of a Conversion to Aflibercept in Eyes with Age-Related Macular Degeneration after Long-Term Ranibizumab Treatment. Klinische Monatsblatter Fur Augenheilkunde, 2015, 232, 560-563.	0.3	4
483	Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. Expert Review of Clinical Pharmacology, 2015, 8, 541-548.	1.3	34
484	Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, The, 2015, 386, 2395-2403.	6.3	154
485	Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis, 2015, 18, 397-432.	3.7	31
486	Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept. Drugs and Aging, 2015, 32, 797-807.	1.3	24
487	Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile. Ophthalmologica, 2015, 234, 195-210.	1.0	9
488	Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth FactorÂTreatment. Ophthalmology, 2015, 122, 2303-2310.	2.5	92
490	Intravitreal Antiâ€"Vascular Endothelial Growth Factor Treatment and the Risk of Thromboembolism. American Journal of Ophthalmology, 2015, 160, 569-580.e5.	1.7	32
491	Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab. Ophthalmology, 2015, 122, 1802-1810.	2.5	58
492	Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration. Eye, 2015, 29, 1141-1151.	1.1	13
493	Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. Current Medical Research and Opinion, 2015, 31, 2031-2042.	0.9	18
494	Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review. BMJ Open, 2015, 5, e007746-e007746.	0.8	20
495	Parainflammation, chronic inflammation, and age-related macular degeneration. Journal of Leukocyte Biology, 2015, 98, 713-725.	1.5	256
496	Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Canadian Journal of Ophthalmology, 2015, 50, 373-377.	0.4	20
497	VEGF Inhibitors for AMD and Diabetic Macular Edema. JAMA - Journal of the American Medical Association, 2015, 314, 2184.	3.8	4
498	Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 160, 1014-1023.e2.	1.7	59

#	Article	IF	Citations
499	Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 2514-2522.	2.5	226
500	Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration. Saudi Journal of Ophthalmology, 2015, 29, 187-191.	0.3	3
501	Response-based individualized medicine for neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2015, 10, 105-112.	0.3	2
502	Scheduled versus Pro Re Nata Dosing in the VIEW Trials. Ophthalmology, 2015, 122, 2497-2503.	2.5	42
503	Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study). BMC Ophthalmology, 2015, 15, 71.	0.6	12
504	Rate of vision loss in neovascular age-related macular degeneration explored. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1859-1865.	1.0	18
505	Induction With Intravitreal Bevacizumab Every Two Weeks in the Management of Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 159, 131-137.	1.7	23
506	Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen. American Journal of Ophthalmology, 2015, 159, 3-8.e1.	1.7	108
507	Regression of Choroidal Neovascularization Results in Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Eyes. American Journal of Ophthalmology, 2015, 159, 9-19.e2.	1.7	45
508	Ocular pulse amplitude and retinal vessel caliber changes after intravitreal ranibizumab. International Ophthalmology, 2015, 35, 657-662.	0.6	7
509	Outcomes of Eyes with Lesions Composed ofÂ>50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology, 2015, 122, 391-398.e5.	2.5	46
510	Age related macular degenerationÂâ€“Âchallenge for future: Pathogenesis and new perspectives for the treatment. European Geriatric Medicine, 2015, 6, 69-75.	1.2	36
511	Drugs in Phase II clinical trials for the treatment of age-related macular degeneration. Expert Opinion on Investigational Drugs, 2015, 24, 183-199.	1.9	47
512	Triple Subconjunctival Bevacizumab Injection for Early Corneal Recurrent Pterygium: One-Year Follow-Up. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 106-113.	0.6	18
513	Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 399-406.	2.5	55
514	Vision-Threatening Lesions Developing with Longer-Term Follow-up after Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 153-161.	2.5	26
515	Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol. Ophthalmology, 2015, 122, 146-152.	2.5	310
516	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clinical Ophthalmology, 2016, 10, 313.	0.9	12

#	Article	IF	Citations
517	Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series. Journal of Ophthalmology, 2016, 2016, 1-6.	0.6	4
518	Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome. Clinical Ophthalmology, 2017, Volume 11, 63-70.	0.9	4
519	PDGF-Inhibition als potenzieller Behandlungsansatz bei okularer Neovaskularisation. Karger Kompass Ophthalmologie, 2016, 2, 54-58.	0.0	0
520	A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clinical Ophthalmology, 2016, 10, 87.	0.9	27
521	Beyond VEGFâ€"The Weisenfeld Lecture. , 2016, 57, 6911.		49
522	Intravitreal Aflibercept for Choroidal Neovascularization in Ocular Sarcoidosis. European Journal of Ophthalmology, 2016, 26, e124-e127.	0.7	7
523	One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement. Clinical Ophthalmology, 2016, 10, 969.	0.9	13
524	A Drug Delivery System for Administration of Antiâ€"TNF-Î± Antibody. Translational Vision Science and Technology, 2016, 5, 11.	1.1	25
525	The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization. , 2016, 57, 2600.		23
526	Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. , 2016, 57, OCT14.		64
527	Effects of Intravitreal Injection of Bevacizumab or Ranibizumab on Systemic Circulation. Journal of Korean Ophthalmological Society, 2016, 57, 429.	0.0	3
528	Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2016, 30, 17.	0.5	7
529	Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2. Clinical Ophthalmology, 2016, 10, 1023.	0.9	19
530	OCT Angiographyâ€"Based Detection and Quantification of the Neovascular Network in Exudative AMD. , 2016, 57, 6342.		33
531	Review of effects of anti-VEGF treatment on refractive error. Eye and Brain, 2016, 8, 135.	3.8	26
532	Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes. Clinical Ophthalmology, 2016, 10, 541.	0.9	15
533	Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment. Clinical Ophthalmology, 2016, Volume 10, 2505-2513.	0.9	4
534	Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. Journal of Ophthalmology, 2016, 2016, 1-13.	0.6	26

#	Article	IF	Citations
535	Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 238-244.	0.4	8
536	DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 308-312.	0.4	9
537	Biomaterials for intraocular sustained drug delivery. , 2016, , 131-147.		0
538	In Vivo Imaging of Fluorescent Probes Linked to Antibodies Against Human and Rat Vascular Endothelial Growth Factor. , 2016, 57, 759.		17
539	Automated Retinal Layer Segmentation Using Spectral Domain Optical Coherence Tomography: Evaluation of Inter-Session Repeatability and Agreement between Devices. PLoS ONE, 2016, 11, e0162001.	1.1	49
540	Trends in the Care of Diabetic Macular Edema: Analysis of a National Cohort. PLoS ONE, 2016, 11, e0149450.	1.1	30
541	Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS ONE, 2016, 11, e0153052.	1.1	57
542	Visual and Anatomic Outcomes after Conversion to Aflibercept in Neovascular Age-Related Macular Degeneration: 12-Month Results. European Journal of Ophthalmology, 2016, 26, 473-478.	0.7	17
543	Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Design, Development and Therapy, 2016, 10, 1857.	2.0	164
544	BRIDGE ARCH-SHAPED SEROUS RETINAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 476-482.	1.0	10
545	AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS. Retina, 2016, 36, 492-498.	1.0	22
546	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 859-867.	1.0	48
547	DYNAMIC CHANGES OF THE ANTERIOR CHAMBER ANGLE PRODUCED BY INTRAVITREAL ANTI-VASCULAR GROWTH FACTOR INJECTIONS. Retina, 2016, 36, 1874-1881.	1.0	22
548	Correspondence. Retina, 2016, 36, e50-e51.	1.0	0
549	CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT. Retina, 2016, 36, 53-58.	1.0	22
550	PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2016, 36, 1843-1850.	1.0	50
551	EVALUATION OF A TELEMEDICINE MODEL TO FOLLOW UP PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 279-284.	1.0	20
552	Aflibercept vs. Ranibizumab: costâ€effectiveness of treatment for wet ageâ€related macular degeneration in Sweden. Acta Ophthalmologica, 2016, 94, 441-448.	0.6	17

#	Article	IF	Citations
553	Effects of commonly used intravitreal antiâ€vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body. Clinical and Experimental Ophthalmology, 2016, 44, 587-596.	1.3	3
554	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. Current Opinion in Ophthalmology, 2016, 27, 224-243.	1.3	14
555	Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review. Ophthalmic Research, 2016, 55, 185-193.	1.0	49
556	Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials. Ophthalmologica, 2016, 236, 193-200.	1.0	10
557	Long-Term Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Diabetic Macular Edema. European Journal of Ophthalmology, 2016, 26, 454-459.	0.7	36
559	Topical Versus Systemic Ocular Drug Delivery. , 2016, , 53-74.		7
560	Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. British Journal of Ophthalmology, 2017, 101, bjophthalmol-2016-308668.	2.1	120
561	UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92â€...976 intravitreal ranibizumab injections. British Journal of Ophthalmology, 2016, 100, 1617-1622.	2.1	17
562	Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. British Journal of Ophthalmology, 2016, 100, 1623-1628.	2.1	104
563	Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. British Journal of Ophthalmology, 2016, 100, 1611-1616.	2.1	7
564	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 1640-1645.	2.1	36
565	Changing from apro re natatreatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 1341-1345.	2.1	43
566	Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2016, 236, 201-206.	1.0	15
567	Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. The Cochrane Library, 2016, 2016, CD011160.	1.5	25
568	VISUALIZING RETINAL PIGMENT EPITHELIUM PHENOTYPES IN THE TRANSITION TO ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, S26-S39.	1.0	55
569	CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, S83-S92.	1.0	36
570	Challenges in Applying the Results of Clinical Trials to Clinical Practice. JAMA Ophthalmology, 2016, 134, 928.	1.4	12
572	Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2016, 167, 1-9.	1.7	28

#	Article	IF	Citations
573	Determining patient preferences in the management of neovascular age-related macular degeneration: a conjoint analysis. Eye, 2016, 30, 698-704.	1.1	22
574	Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016, 123, 1530-1540.	2.5	92
575	Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2016, 134, 545.	1.4	13
576	Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies. Drug Safety, 2016, 39, 517-541.	1.4	17
577	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis, 2016, 19, 257-273.	3.7	22
578	Real-world utilization of ranibizumab in wet age-related macular degeneration patients from Canada. Canadian Journal of Ophthalmology, 2016, 51, 55-57.	0.4	1
579	Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2655-64.	3.3	442
580	Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology, 2016, 134, 674.	1.4	16
581	Endophthalmitis. , 2016, , .		3
583	Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. Advances in Therapy, 2016, 33, 715-726.	1.3	11
584	Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health. Seminars in Ophthalmology, 2016, 31, 378-384.	0.8	15
585	Five-Year Outcomes with Antiâ€“Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 1751-1761.	2.5	541
586	Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development. Drug Discovery Today, 2016, 21, 1019-1026.	3.2	4
588	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. Essentials in Ophthalmology, 2016, , 31-65.	0.0	0
589	Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye, 2016, 30, 1063-1071.	1.1	40
590	Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid. Ophthalmology, 2016, 123, 1856-1864.	2.5	65
591	Canadian preference and trends survey results for anti-VEGF treatment of macular edema. Canadian Journal of Ophthalmology, 2016, 51, 233-237.	0.4	6
592	Development and pathological changes of neurovascular unit regulated by hypoxia response in the retina. Progress in Brain Research, 2016, 225, 201-211.	0.9	11

#	Article	IF	Citations
593	Method development to quantify Bv8 expression in circulating CD11b+ cells in patients with neovascular age-related macular degeneration (nvAMD) exhibiting Anti-VEGF refractoriness. Experimental Eye Research, 2016, 148, 45-51.	1.2	4
594	Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology, 2016, 123, 2545-2553.	2.5	59
595	Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous. Journal of Controlled Release, 2016, 243, 78-85.	4.8	6
597	Physician-Industry Interactions and Antiâ€"Vascular Endothelial Growth Factor Use Among US Ophthalmologists. JAMA Ophthalmology, 2016, 134, 897.	1.4	58
598	A Revised Hemodynamic Theory of Age-Related Macular Degeneration. Trends in Molecular Medicine, 2016, 22, 656-670.	3.5	45
599	Costâ€effectiveness of treating wet ageâ€related macular degeneration at the Kuopio University Hospital in Finland based on a twoâ€eye Markov transition model. Acta Ophthalmologica, 2016, 94, 652-656.	0.6	19
600	Intraocular Pressure Spikes after Aflibercept Intravitreal Injections. Ophthalmologica, 2016, 236, 43-47.	1.0	20
601	Antiâ€"Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease. Ophthalmology, 2016, 123, S78-S88.	2.5	100
602	Reply. American Journal of Ophthalmology, 2016, 170, 247-248.	1.7	0
604	The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. Eye, 2016, 30, 1462-1468.	1.1	16
605	Anti-angiogenic Therapy for Retinal Disease. Handbook of Experimental Pharmacology, 2016, 242, 271-307.	0.9	38
606	Strategies for Improving Patient Comfort During Intravitreal Injections: Results from a Survey-Based Study. Ophthalmology and Therapy, 2016, 5, 183-190.	1.0	17
607	Pharmacogenomics of Response to Anti-VEGF Therapy in Exudative Age-Related Macular Degeneration. , 2016, , 63-95.		0
608	Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial. BMJ Open, 2016, 6, e011121.	0.8	9
609	Ranibizumab versus Bevacizumab for the Treatment of Idiopathic Choroidal Neovascularization: 2-Year Results. European Journal of Ophthalmology, 2016, 26, 262-267.	0.7	7
610	Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. The Cochrane Library, 2016, , .	1.5	4
611	Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. BMC Ophthalmology, 2016, 16, 169.	0.6	11
612	An Update in the Management of Proliferative Diabetic Retinopathy. International Ophthalmology Clinics, 2016, 56, 209-225.	0.3	3

#	Article	IF	Citations
613	Gene Therapy for Age-Related Macular Degeneration. Asia-Pacific Journal of Ophthalmology, 2016, 5, 300-303.	1.3	14
614	Stereotactic radiotherapy in neovascular age-related macular degeneration. Medicine (United States), 2016, 95, e5729.	0.4	16
615	Targeting Platelet-Derived Growth Factor Receptor Î²+ Scaffold Formation Inhibits Choroidal Neovascularization. American Journal of Pathology, 2016, 186, 1890-1899.	1.9	28
616	Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT). Ophthalmology, 2016, 123, 1287-1296.	2.5	12
618	Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1681-1692.	1.0	1
619	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. American Journal of Ophthalmology, 2016, 168, 1-12.	1.7	92
620	The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmology, 2016, 16, 31.	0.6	77
621	Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series. International Journal of Retina and Vitreous, 2016, 2, 2.	0.9	14
624	RETROSPECTIVE REVIEW OF LUCENTIS â€œTREAT AND EXTENDâ€•PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 272-278.	1.0	10
625	Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. Experimental Eye Research, 2016, 145, 248-257.	1.2	17
626	Targeting VEGF in eye neovascularization: What's new?. Pharmacological Research, 2016, 103, 253-269.	3.1	137
627	Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1519-1527.	1.0	10
628	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	21.5	724
629	Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison ofÂAge-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016, 123, 352-360.	2.5	37
630	A multimodal approach to diabetic macular edema. Journal of Diabetes and Its Complications, 2016, 30, 545-553.	1.2	11
631	Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Japanese Journal of Ophthalmology, 2016, 60, 42-50.	0.9	11
632	Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye, 2016, 30, 270-286.	1.1	106
633	High Variation of Intravitreal Injection Rates and Medicare Antiâ€“Vascular Endothelial Growth Factor Payments per Injection in the United States. Ophthalmology, 2016, 123, 1257-1262.	2.5	45

#	Article	IF	Citations
634	The role of Aflibercept in the management of age-related macular degeneration. Expert Opinion on Biological Therapy, 2016, 16, 699-709.	1.4	7
635	Optical Coherence Tomography Angiography of Asymptomatic Neovascularization in Intermediate Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 1309-1319.	2.5	230
636	Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2016, 235, 42-48.	1.0	19
637	Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. Biochemical Pharmacology, 2016, 103, 129-139.	2.0	18
638	Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutaneous and Ocular Toxicology, 2016, 35, 310-314.	0.5	30
639	Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016, 123, 858-864.	2.5	12
640	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Ophthalmology, 2016, 123, 1351-1359.	2.5	731
641	Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Ophthalmic Epidemiology, 2016, 23, 71-79.	0.8	48
642	Treatment for neovascular age related macular degeneration: The state of the art. European Journal of Pharmacology, 2016, 787, 78-83.	1.7	21
643	Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1497-1503.	1.0	38
644	Macular Morphology and Visual Acuity inÂtheÂSecond Year of the Comparison of Age-RelatedÂMacular Degeneration Treatments Trials. Ophthalmology, 2016, 123, 865-875.	2.5	181
645	A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 78-85.	2.5	82
646	A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 914-917.	2.1	98
647	Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. Expert Opinion on Drug Safety, 2016, 15, 75-87.	1.0	8
648	Predictive Value of Retinal Morphology forÂVisual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology, 2016, 123, 60-69.	2.5	97
649	Effect of Regulatory Requirement for Patient-Specific Prescriptions for Off-Label Medications on the Use of Intravitreal Bevacizumab. JAMA Ophthalmology, 2016, 134, 45.	1.4	5
650	Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. American Journal of Ophthalmology, 2016, 161, 94-103.e1.	1.7	36
651	Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Japanese Journal of Ophthalmology, 2016, 60, 35-41.	0.9	19

#	Article	IF	Citations
652	Intravitreal Bevacizumab Versus Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 70-77.e1.	2.5	62
653	Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol. Ophthalmology, 2016, 123, 51-59.	2.5	134
654	Complement pathway biomarkers and age-related macular degeneration. Eye, 2016, 30, 1-14.	1.1	30
655	Connexin43 in retinal injury and disease. Progress in Retinal and Eye Research, 2016, 51, 41-68.	7.3	86
656	Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 645-651.	1.0	11
657	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Progress in Retinal and Eye Research, 2016, 50, 1-24.	7.3	284
658	Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 445-454.	1.0	35
659	Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 23-30.	1.0	31
660	Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment. Seminars in Ophthalmology, 2017, 32, 309-315.	0.8	8
661	Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular ageâ€related macular degeneration: a comparative 12 Month study. Acta Ophthalmologica, 2017, 95, e67-e72.	0.6	58
662	Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 923-934.	1.0	8
663	Impacto funcional del tratamiento con ranibizumab bajo una estrategia reactiva en pacientes con degeneraciÃ³n macular asociada a la edad exudativa neovascular. Archivos De La Sociedad Espanola De Oftalmologia, 2017, 92, 120-127.	0.1	1
664	Functional impact of treatment with ranibizumab under a reactive strategy in patients with neovascular age-related macular degeneration. Archivos De La Sociedad Espanola De Oftalmologia, 2017, 92, 120-127.	0.1	1
665	Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries. Ophthalmology Retina, 2017, 1, 19-24.	1.2	8
666	Phase I/II Randomized Study of Proton Beam with Antiâ€“Vascular Endothelial Growth Factor for Exudative Age-Related Macular Degeneration. Ophthalmology Retina, 2017, 1, 217-226.	1.2	6
667	Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study. Japanese Journal of Ophthalmology, 2017, 61, 159-168.	0.9	7
668	Response of vascular pigment epithelium detachment due to ageâ€related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre <scp>RECOVER</scp> study. Acta Ophthalmologica, 2017, 95, 683-689.	0.6	13
669	The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. JAMA Ophthalmology, 2017, 135, 268.	1.4	39

#	Article	IF	Citations
670	Vision Preservation in Eyes of Polypoidal Choroidal Vasculopathy with Low-Dose Intravitreal Triamcinolone Acetonide. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 42-49.	0.6	4
671	Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2017, 1, 314-321.	1.2	79
672	Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine, 2017, 96, 8-15.	1.4	19
673	Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, etÂal.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials (Ophthalmology 2016;123:1751-1761). Ophthalmology, 2017, 124, e31-e32.	2.5	19
675	Optical coherence tomographic angiography of choroidal neovascularization ill-defined with fluorescein angiography. British Journal of Ophthalmology, 2017, 101, 45-50.	2.1	23
677	Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. American Journal of Ophthalmology, 2017, 177, 150-158.	1.7	57
678	Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. BMC Ophthalmology, 2017, 17, 7.	0.6	54
679	Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. British Journal of Ophthalmology, 2017, 101, 976-984.	2.1	25
680	TREAT-AND-EXTEND REGIMEN USING RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2017, 37, 561-567.	1.0	14
681	UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. British Journal of Ophthalmology, 2017, 101, 1683-1688.	2.1	37
682	Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy. Current Ophthalmology Reports, 2017, 5, 141-148.	0.5	9
683	A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Ophthalmology and Therapy, 2017, 6, 79-92.	1.0	41
684	Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 2017, 237, 185-222.	1.0	456
685	Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease. JAMA Ophthalmology, 2017, 135, 586.	1.4	84
686	Neovascular Age-Related Macular Degeneration. , 2017, , 183-203.		0
687	Antiâ€vascular endothelial growth factor treatment for neovascular ageâ€related macular degeneration: Comparison of Ageâ€related Macular Degeneration Treatments Trials 5Âyear outcomes and implication for clinical practice. Clinical and Experimental Ophthalmology, 2017, 45, 333-335.	1.3	1
688	Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet, The, 2017, 390, 50-61.	6.3	167
689	Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease. , 2017, , 79-94.		0

#	Article	IF	Citations
690	Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation. Ophthalmology, 2017, 124, 1332-1339.	2.5	23
691	Simultaneous Dexamethasone Intravitreal Implant and Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration Resistant to Anti-VEGF Monotherapy. Journal of Vitreoretinal Diseases, 2017, 1, 65-74.	0.2	14
692	Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal antiâ€“vascular endothelial growth factor therapy of macular diseases. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1259-1273.	1.0	113
693	Relationship Between Visual Acuity and Retinal Thickness During Antiâ€“Vascular Endothelial Growth Factor Therapy for Retinal Diseases. American Journal of Ophthalmology, 2017, 180, 8-17.	1.7	60
694	INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB. Retina, 2017, 37, 1185-1192.	1.0	11
695	Twoâ€year functional and anatomical results after converting treatment resistant eyes with exudative ageâ€related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmologica, 2017, 95, 460-463.	0.6	19
696	LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 951-961.	1.0	22
697	Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. JAMA Ophthalmology, 2017, 135, 452.	1.4	38
698	Gene Delivery of Calreticulin Anti-Angiogenic Domain Attenuates the Development of Choroidal Neovascularization in Rats. Human Gene Therapy, 2017, 28, 403-414.	1.4	3
700	Treatment Patterns for Myopic Choroidal Neovascularization in the United States. Ophthalmology, 2017, 124, 935-943.	2.5	24
701	Early Response to Ranibizumab Is Predictive of Treatment Demand after a Therapeutic Switch to Aflibercept. Ophthalmology Retina, 2017, 1, 210-216.	1.2	2
702	Prevalence and quantification of geographic atrophy associated with newly diagnosed and treatment-naÃ¯ve exudative age-related macular degeneration. British Journal of Ophthalmology, 2017, 101, 438-444.	2.1	12
703	SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina, 2017, 37, 1847-1858.	1.0	234
704	Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology, 2017, 124, 352-358.	2.5	83
705	A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open, 2017, 7, e018289.	0.8	32
706	A Multimodal Imaging Guide to the Evaluation and Management of Neovascular Age-Related Macular Degeneration. ESASO Course Series, 2017, , 14-31.	0.1	0
707	Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Ophthalmologica, 2017, 238, 217-225.	1.0	13
708	Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells. Scientific Reports, 2017, 7, 12242.	1.6	26

#	Article	IF	Citations
709	Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration. Ophthalmologica, 2017, 238, 236-242.	1.0	16
710	Current Best Clinical Practicesâ€"Management of Neovascular AMD. Journal of Vitreoretinal Diseases, 2017, 1, 294-297.	0.2	14
711	Risk of age-related macular degeneration in patients with prostate cancer: a nationwide, population-based cohort study. Annals of Oncology, 2017, 28, 2575-2580.	0.6	8
712	Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2157-2163.	1.0	6
713	An 8â€year followâ€up of antiâ€vascular endothelial growth factor treatment with a treatâ€andâ€extend modality for neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2017, 95, 796-802.	0.6	64
714	Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Research, 2017, 58, 18-26.	1.0	3
715	Principles of pharmacology in the eye. British Journal of Pharmacology, 2017, 174, 4205-4223.	2.7	137
716	The Finnish national guideline for diagnosis, treatment and followâ€up of patients with wet ageâ€related macular degeneration. Acta Ophthalmologica, 2017, 95, 1-9.	0.6	28
717	Gene therapy for age-related macular degeneration. Expert Opinion on Biological Therapy, 2017, 17, 1235-1244.	1.4	53
718	Plasma lipoprotein subfraction concentrations are associated with lipid metabolism and age-related macular degeneration. Journal of Lipid Research, 2017, 58, 1785-1796.	2.0	22
719	Serious Adverse Events with Bevacizumab or Ranibizumab for Age-Related Macular Degeneration: Meta-analysis of Individual Patient Data. Ophthalmology Retina, 2017, 1, 375-381.	1.2	11
720	ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2091-2098.	1.0	11
722	RETICULAR PSEUDODRUSEN ARE NOT A PREDICTIVE FACTOR FOR THE 1-YEAR RESPONSE TO INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 53-59.	1.0	10
723	NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2017, 37, 257-264.	1.0	5
724	MACULAR CHOROIDAL VOLUME CHANGES AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 2262-2268.	1.0	3
725	Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration. Medicine (United States), 2017, 96, e6422.	0.4	6
726	Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. Eye, 2017, 31, 1582-1588.	1.1	27
727	INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 1337-1344.	1.0	13

#	Article	IF	Citations
728	SYSTEMIC BETA-BLOCKERS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 41-46.	1.0	11
729	OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC. Retina, 2017, 37, 1371-1376.	1.0	13
730	24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. BMC Ophthalmology, 2017, 17, 58.	0.6	23
731	Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration. International Journal of Retina and Vitreous, 2017, 3, 6.	0.9	15
732	Induced pluripotent stem cell-based therapy for age-related macular degeneration. Expert Opinion on Biological Therapy, 2017, 17, 1113-1126.	1.4	26
733	Identification of different macrophage subpopulations with distinct activities in a mouse model of oxygen-induced retinopathy. International Journal of Molecular Medicine, 2017, 40, 281-292.	1.8	48
734	Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2017, 124, 97-104.	2.5	158
735	Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2017, 124, 224-234.	2.5	118
736	Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab. Ophthalmology, 2017, 124, 215-223.	2.5	54
737	Advances in bone marrow stem cell therapy for retinal dysfunction. Progress in Retinal and Eye Research, 2017, 56, 148-165.	7.3	89
738	Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. Journal of Medical Economics, 2017, 20, 204-212.	1.0	10
739	A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. International Ophthalmology, 2017, 37, 1205-1214.	0.6	27
740	Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab. Wiener Klinische Wochenschrift, 2017, 129, 351-357.	1.0	1
741	Recent perspectives on the delivery of biologics to back of the eye. Expert Opinion on Drug Delivery, 2017, 14, 631-645.	2.4	49
742	Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 475-484.	1.0	12
743	Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. Japanese Journal of Ophthalmology, 2017, 61, 74-83.	0.9	16
744	Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. American Journal of Ophthalmology, 2017, 173, 56-63.	1.7	29
745	Current advances in the treatment of neovascular age-related macular degeneration. Expert Opinion on Drug Delivery, 2017, 14, 273-282.	2.4	63

#	Article	IF	Citations
746	High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 709-717.	1.0	9
747	Seven-year Trends in Visual Acuity at First Presentation in Patients with Neovascular AMD. Ophthalmology, 2017, 124, 270-272.	2.5	5
748	Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis. Ophthalmic Research, 2017, 58, 49-55.	1.0	5
749	Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration. Medicine (United States), 2017, 96, e9345.	0.4	9
750	Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration. TÃ¼rk Oftalmoloji Dergisi, 2017, 47, 205-210.	0.4	69
751	Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel. Asia-Pacific Journal of Ophthalmology, 2017, 6, 296-302.	1.3	20
752	Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. Asia-Pacific Journal of Ophthalmology, 2017, 6, 561-568.	1.3	27
753	The VEGF Treatment of AMD Switch Study (The vTAS Study). Asia-Pacific Journal of Ophthalmology, 2017, 6, 481-487.	1.3	4
754	Comparison of Choroidal Thickness Change between Ranibizumab and Aflibercept in Age-related Macular Degeneration: Six Month Results. Journal of Korean Ophthalmological Society, 2017, 58, 296.	0.0	1
755	Recent developments in age-related macular degeneration: a review. Clinical Interventions in Aging, 2017, Volume 12, 1313-1330.	1.3	285
756	A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. International Journal of Molecular Sciences, 2017, 18, 1786.	1.8	119
757	The Impact of Switching Anti-Vascular Endothelial Growth Factor Therapy in the Management of Exudative Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 859-869.	0.4	2
758	Safety and Effectiveness of Cataract Surgery with Simultaneous Intravitreal Anti-VEGF in Patients with Previously Treated Exudative Age-Related Macular Degeneration. Acta Medica Portuguesa, 2017, 30, 127-133.	0.2	6
759	Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept. Journal of Ophthalmology, 2017, 2017, 1-8.	0.6	6
760	Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes. Journal of Ophthalmology, 2017, 2017, 1-10.	0.6	27
761	Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model. , 2017, 58, 5636.		32
762	Clinical Experience of Switching Anti-VEGF Therapy from Ranibizumab to Aflibercept in Age-Related Choroidal Neovascularization. European Journal of Ophthalmology, 2017, 27, 342-345.	0.7	7
763	Effects of bevacizumab on endoplasmic reticulum stress in hypoxic retinal pigment epithelial cells. PLoS ONE, 2017, 12, e0179048.	1.1	6

#	Article	IF	Citations
764	Advanced quantitative analysis of the sub-retinal pigment epithelial space in recurrent neovascular age-related macular degeneration. PLoS ONE, 2017, 12, e0186955.	1.1	6
765	Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration. PLoS ONE, 2017, 12, e0185070.	1.1	5
766	Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. BMC Ophthalmology, 2017, 17, 189.	0.6	26
767	Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 780-784.	0.4	26
768	A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal. Acta Medica Portuguesa, 2017, 30, 449-456.	0.2	4
769	Efficacy and safety of ranibizumab for wet age-related macular degeneration in Chinese patients. International Journal of Ophthalmology, 2017, 10, 91-97.	0.5	6
770	Fourteen Anti-vascular Endothelial Growth Factor Injections for Age-related Macular Degeneration: Ending Period and Clinical Outcome. Journal of Korean Ophthalmological Society, 2017, 58, 1042.	0.0	2
771	Roles of Hypoxia Response in Retinal Development and Pathophysiology. Keio Journal of Medicine, 2017, 67, 1-9.	0.5	15
772	Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. , 2017, 58, 1893.		43
773	Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. Clinical Ophthalmology, 2017, Volume 11, 223-231.	0.9	13
774	Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clinical Ophthalmology, 2017, Volume 11, 161-177.	0.9	44
775	Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion. Korean Journal of Ophthalmology: KJO, 2017, 31, 108.	0.5	6
776	Nicotinamide: a novel treatment for age-related macular degeneration?. Stem Cell Investigation, 2017, 4, 86-86.	1.3	6
777	Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 651-663.	1.0	24
778	Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Survey of Ophthalmology, 2018, 63, 638-645.	1.7	41
779	Antiâ€vascular endothelial growth factors treatment of wet ageâ€related macular degeneration: from neurophysiology to costâ€effectiveness. Acta Ophthalmologica, 2018, 96, 1-46.	0.6	2
780	Real-world Outcomes of Antiâ€“Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. Ophthalmology Retina, 2018, 2, 645-653.	1.2	63
781	c-Jun-mediated microRNA-302d-3p induces RPE dedifferentiation by targeting p21Waf1/Cip1. Cell Death and Disease, 2018, 9, 451.	2.7	15

#	Article	IF	Citations
782	Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration. American Journal of Ophthalmology, 2018, 191, 135-139.	1.7	33
783	Relationship Between Claims Data and the Preferences and Trends Survey: An Analysis of Anti-Vascular Endothelial Growth Factor Medication Choice for Age-Related Macular Degeneration. Journal of Vitreoretinal Diseases, 2018, 2, 96-99.	0.2	3
784	Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2018, 125, 1037-1046.	2.5	60
785	Evolution of Intravitreal Therapy for Retinal Diseasesâ€"From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture. American Journal of Ophthalmology, 2018, 191, xli-lviii.	1.7	32
786	Clinical pharmacology of intravitreal anti-VEGF drugs. Eye, 2018, 32, 1010-1020.	1.1	143
787	The Real-World Effect of Intravitreous Antiâ€"Vascular Endothelial Growth Factor Drugs on Intraocular Pressure. Ophthalmology, 2018, 125, 676-682.	2.5	53
788	Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Antiâ€"VEGF Injections Using a Treat-Extend-Stop Protocol. Ophthalmology, 2018, 125, 1047-1053.	2.5	59
789	Long-term Progression of Type 1 Neovascularization in Age-related Macular Degeneration Using Optical Coherence Tomography Angiography. American Journal of Ophthalmology, 2018, 187, 10-20.	1.7	87
790	Linking OCT, Angiographic, and Photographic Lesion Components in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 481-493.	1.2	10
791	Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Antiâ€"Vascular Endothelial Growth Factor. Ophthalmology Retina, 2018, 2, 550-557.	1.2	12
792	Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmic Epidemiology, 2018, 25, 176-182.	0.8	18
793	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chemical Reviews, 2018, 118, 1599-1663.	23.0	64
794	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Progress in Retinal and Eye Research, 2018, 65, 127-146.	7.3	205
795	A Discussion of Commercially Available Intra-ocular Telescopic Implants for Patients with Age-Related Macular Degeneration. Ophthalmology and Therapy, 2018, 7, 33-48.	1.0	12
796	A comparative study to determine the optimal intravitreal injection angle to the eye: A computational fluid-structure interaction model. Technology and Health Care, 2018, 26, 483-498.	0.5	11
797	Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration. Molecular Diagnosis and Therapy, 2018, 22, 315-343.	1.6	26
798	Overexpression of Annexin A2 Receptor Inhibits Neovascularization via the Promotion of KrÃ¼ppel-Like Transcription Factor 2. Cellular Physiology and Biochemistry, 2018, 46, 1617-1627.	1.1	11
799	The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 667-675.	1.2	7

#	Article	IF	Citations
800	Fluorescein Angiography Does Not Alter the Initial Clinical Management of Choroidal Neovascularization in Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 659-666.	1.2	6
801	Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Antiâ€"Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmology, 2018, 136, 557.	1.4	48
802	Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints. American Journal of Ophthalmology, 2018, 189, 127-138.	1.7	84
803	Topical antibiotics and intravitreal injections. Acta Ophthalmologica, 2018, 96, 435-441.	0.6	25
804	TWO YEAR OUTCOMES OF â€œTREAT AND EXTENDâ€•INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 20-28.	1.0	83
805	ANGIOPOIETIN-LIKE 4 CORRELATES WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2018, 38, 523-530.	1.0	14
807	Factors associated with multiple recurrences of nonspecific orbital inflammation aka orbital pseudotumor. International Ophthalmology, 2018, 38, 1485-1495.	0.6	8
808	Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for ageâ€related macular degeneration. Clinical and Experimental Ophthalmology, 2018, 46, 46-53.	1.3	3
809	LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2018, 38, 516-522.	1.0	12
810	OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR MORE YEARS. Retina, 2018, 38, 1500-1508.	1.0	23
811	Reply to: â€˜Comment on: â€˜One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degenerationâ€™. Eye, 2018, 32, 479-481.	1.1	0
812	RESIDUAL CHOROIDAL VESSELS IN ATROPHY CAN MASQUERADE AS CHOROIDAL NEOVASCULARIZATION ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina, 2018, 38, 1289-1300.	1.0	21
813	Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 57-65.	2.5	202
814	INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION. Retina, 2018, 38, 2150-2158.	1.0	15
815	Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents. Ophthalmologica, 2018, 239, 45-51.	1.0	0
816	The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review. Survey of Ophthalmology, 2018, 63, 281-295.	1.7	59
817	Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmology Retina, 2018, 2, 118-127.	1.2	21
818	Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration ManagedÂwith a Treatâ€"Extendâ€"Stop Protocol. Ophthalmology Retina, 2018, 2, 225-230.	1.2	45

#	Article	IF	Citations
819	The Impact of the Vitreomacular Interface in Neovascular Age-Related Macular Degeneration in a Treat-and-Extend Regimen with Exit Strategy. Ophthalmology Retina, 2018, 2, 288-294.	1.2	13
820	Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes. Current Eye Research, 2018, 43, 391-396.	0.7	23
821	Treatâ€andâ€extend versus everyâ€otherâ€month regimens with aflibercept in ageâ€related macular degeneration. Acta Ophthalmologica, 2018, 96, e393-e398.	0.6	33
822	Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Antiâ€"VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology, 2018, 125, 522-528.	2.5	111
823	Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye, 2018, 32, 391-399.	1.1	31
824	Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. Ophthalmology Retina, 2018, 2, 525-530.	1.2	42
826	Ageâ€related macular degeneration: using morphological predictors to modify current treatment protocols. Acta Ophthalmologica, 2018, 96, 120-133.	0.6	60
827	Endophthalmitis Prophylaxis: Different Practices from Around the World. , 2018, , 345-356.		1
828	Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. British Journal of Ophthalmology, 2018, 102, 460-464.	2.1	34
829	Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration. Clinical Ophthalmology, 2019, Volume 13, 17-23.	0.9	2
830	VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. JCI Insight, 2018, 3, .	2.3	22
831	One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis. Medicine (United States), 2018, 97, e11737.	0.4	4
832	Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. Translational Vision Science and Technology, 2018, 7, 23.	1.1	8
833	Age related macular degeneration: from evidence based-care to experimental models. Annals of Eye Science, 0, 3, 1-1.	1.1	5
834	Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey. International Journal of Ophthalmology, 2018, 11, 267-273.	0.5	4
835	Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration. International Journal of Ophthalmology, 2018, 11, 645-649.	0.5	3
836	Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain. International Journal of Molecular Sciences, 2018, 19, 2993.	1.8	5
837	Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. , 2018, 59, 5836.		61

#	Article	IF	Citations
838	A Combination Therapy Targeting Endoglin and VEGF-A Prevents Subretinal Fibro-Neovascularization Caused by Induced MÃ¼ller Cell Disruption. , 2018, 59, 6075.		11
839	The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab. Journal of Current Ophthalmology, 2018, 30, 337-342.	0.3	2
840	Racial Differences in Age-Related Macular Degeneration and Associated Antiâ€“Vascular Endothelial Growth Factor Intravitreal Injections among Medicare Beneficiaries. Ophthalmology Retina, 2018, 2, 1188-1195.	1.2	10
841	Drug-induced uveitis. Current Opinion in Ophthalmology, 2018, 29, 588-603.	1.3	59
842	Age-related macular degeneration. Lancet, The, 2018, 392, 1147-1159.	6.3	958
843	Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Japanese Journal of Ophthalmology, 2018, 62, 652-658.	0.9	12
844	The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea. PLoS ONE, 2018, 13, e0206690.	1.1	11
845	Real study: Re-treatment evaluated on visual acuity for Lucentis Â® in neovascular AMD. Journal Francais D'Ophtalmologie, 2018, 41, 397-401.	0.2	1
846	One-step solid-oil-water emulsion for sustained bioactive ranibizumab release. Expert Opinion on Drug Delivery, 2018, 15, 1143-1156.	2.4	5
847	Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Antiâ€“Vascular Endothelial Growth Factor Injections. JAMA Ophthalmology, 2018, 136, 1251.	1.4	70
848	Early Recurrent Hemorrhage in Submacular Hemorrhage Secondary to Type 3 Neovascularization or Retinal Angiomatous Proliferation: Incidence and Influence on Visual Prognosis. Seminars in Ophthalmology, 2018, 33, 820-828.	0.8	11
849	Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration. Clinical Ophthalmology, 2018, Volume 12, 369-375.	0.9	2
850	The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration. International Journal of Molecular Sciences, 2018, 19, 2611.	1.8	22
851	Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study. Journal of Ophthalmology, 2018, 2018, 1-8.	0.6	18
852	Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. Clinical Ophthalmology, 2018, Volume 12, 593-600.	0.9	11
853	Management of Macular Hemorrhage. , 2018, , .		1
854	Association of Genetic Variants With Response to Antiâ€“Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. JAMA Ophthalmology, 2018, 136, 875.	1.4	30
855	Outcomes of Cataract Surgery in Patients With Exudative Age-related Macular Degeneration and Macular Fluid. American Journal of Ophthalmology, 2018, 192, 91-97.	1.7	18

#	Article	IF	Citations
856	Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. American Journal of Ophthalmology, 2018, 192, 84-90.	1.7	5
857	Intravitreal aflibercept: its role in treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2018, 13, 75-86.	0.3	1
858	Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen. Journal of Ophthalmology, 2018, 2018, 1-7.	0.6	25
859	Potential effect on molecular pathways in different targeted genes in the VEGF family in retina - From the genomic point of view. Experimental Eye Research, 2018, 176, 78-87.	1.2	4
860	Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study. BMC Ophthalmology, 2018, 18, 181.	0.6	2
861	Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1â€‰+â€‰PRN regimen. BMC Ophthalmology, 2018, 18, 144.	0.6	8
862	Fewer Functional Deficits and Reduced Cell Death after Ranibizumab Treatment in a Retinal Ischemia Model. International Journal of Molecular Sciences, 2018, 19, 1636.	1.8	23
863	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmology, 2018, 18, 130.	0.6	38
864	Overview of Antibody Drug Delivery. Pharmaceutics, 2018, 10, 83.	2.0	104
865	Frequencies of human leukocyte antigen alleles and haplotypes among Japanese patients with age-related macular degeneration. Japanese Journal of Ophthalmology, 2018, 62, 568-575.	0.9	5
866	Intravitreal dexamethasone implants for diabetic macular edema. International Journal of Ophthalmology, 2018, 11, 77-82.	0.5	29
867	Endophthalmitis Following Intravitreal Injection. Current Ophthalmology Reports, 2018, 6, 145-151.	0.5	7
868	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan. Scientific Reports, 2018, 8, 7486.	1.6	7
869	Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study. Clinical Drug Investigation, 2018, 38, 853-865.	1.1	10
870	14 Age-Related Macular Degeneration. , 2018, , .		0
871	37 Intravitreal Injections. , 2018, , .		0
872	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. Journal of Managed Care & Specialty Pharmacy, 2018, 24, S3-S15.	0.5	89
873	Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities. Pharmaceutics, 2018, 10, 21.	2.0	37

#	Article	IF	Citations
874	Volume-Rendered Projection-Resolved OCT Angiography: 3D Lesion Complexity Is Associated With Therapy Response in Wet Age-Related Macular Degeneration. , 2018, 59, 1944.		20
875	New Therapies of Neovascular AMDâ€"Beyond Anti-VEGFs. Vision (Switzerland), 2018, 2, 31.	0.5	9
877	Macular Translocation. , 2018, , 73-82.		0
878	A systematic review on the quality, validity and usefulness of current costâ€effectiveness studies for treatments of neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2018, 96, 770-778.	0.6	13
879	Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review. Eye, 2018, 32, 1423-1431.	1.1	23
880	Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1. Ophthalmologica, 2018, 240, 99-105.	1.0	19
881	Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1623-1629.	1.0	13
883	Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2019, 103, 617-622.	2.1	22
884	Systemic side effects after intravitreal administration of antivascular endothelial growth factors for neovascular age-related macular degeneration. Spektrum Der Augenheilkunde, 2019, 33, 110-116.	0.2	0
885	Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trial. British Journal of Ophthalmology, 2019, 103, 469-474.	2.1	12
886	Spectral Domain Optical Coherence Tomography Allows the Unification of Clinical Decision Making for the Evaluation of Choroidal Neovascularization Activity. Ophthalmologica, 2019, 241, 32-37.	1.0	4
888	Time trends, disease patterns and gender imbalance in the top 100 most cited articles in ophthalmology. British Journal of Ophthalmology, 2019, 103, 18-25.	2.1	21
889	Antiâ€"Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmology Retina, 2019, 3, 744-752.	1.2	47
890	Clinical Changes after Switching from Ranibizumab/Aflibercept to Bevacizumab in Exudative Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2019, 60, 40.	0.0	2
891	Self-Assembling Topical Nanomicellar Formulation to Improve Curcumin Absorption Across Ocular Tissues. AAPS PharmSciTech, 2019, 20, 254.	1.5	29
892	In situ antibody-loaded hydrogel for intravitreal delivery. European Journal of Pharmaceutical Sciences, 2019, 137, 104993.	1.9	27
893	The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2019, 3, 1045-1055.	1.2	28
894	Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration . Clinical Ophthalmology, 2019, Volume 13, 1323-1329.	0.9	42

#	Article	IF	Citations
895	Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration . Clinical Ophthalmology, 2019, Volume 13, 1289-1295.	0.9	2
896	Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4. Ophthalmology Retina, 2019, 3, 326-335.	1.2	14
897	Off-label use of bevacizumab in the treatment of retinal disease: ethical implications. Journal of Medical Ethics, 2019, 45, 668-672.	1.0	2
898	Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision (Switzerland), 2019, 3, 41.	0.5	16
899	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832.	1.5	54
900	Fellow-Eye Conversion and Treatment in Exudative Age-Related Macular Degeneration. Journal of Vitreoretinal Diseases, 2019, 3, 438-444.	0.2	3
901	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane Library, 2019, 2019, CD005139.	1.5	116
902	Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease. Molecular Therapy - Nucleic Acids, 2019, 17, 819-828.	2.3	37
903	Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion. JAMA Ophthalmology, 2019, 137, 1256.	1.4	80
904	Hydrodynamics of Intravitreal Injections into Liquid Vitreous Substitutes. Pharmaceutics, 2019, 11, 371.	2.0	14
905	Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opinion on Biological Therapy, 2019, 19, 335-342.	1.4	81
906	Association of Intravitreal Antiâ€"Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration. JAMA Ophthalmology, 2019, 137, 483.	1.4	41
907	Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy. Drug Discovery Today, 2019, 24, 1627-1636.	3.2	23
908	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2019, 137, 372.	1.4	95
909	COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB. Retina, 2019, 39, 2004-2011.	1.0	29
910	Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1411-1418.	1.0	15
911	One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration. Ophthalmic Research, 2019, 62, 93-100.	1.0	1
912	Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure. Cutaneous and Ocular Toxicology, 2019, 38, 344-348.	0.5	12

#	Article	IF	Citations
913	Retinal function determined by flicker ERGs before and soon after intravitreal injection of anti-VEGF agents. BMC Ophthalmology, 2019, 19, 129.	0.6	8
914	Resveratrol and the Human Retina. , 2019, , 127-145.		0
915	Two-Year Risk of Exudation in Eyes with Nonexudative Age-Related Macular Degeneration and Subclinical Neovascularization Detected with Swept Source Optical Coherence Tomography Angiography. American Journal of Ophthalmology, 2019, 208, 1-11.	1.7	57
916	One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: a retrospective cohort study and an open science resource. BMJ Open, 2019, 9, e027441.	0.8	25
917	Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opinion on Biological Therapy, 2019, 19, 735-751.	1.4	18
918	A novel electro-chemotactic approach to impact the directional migration of transplantable retinal progenitor cells. Experimental Eye Research, 2019, 185, 107688.	1.2	14
919	The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 1141-1154.	2.5	201
920	The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials. Experimental Eye Research, 2019, 184, 266-277.	1.2	41
921	Optical coherence tomography angiography image quality assessment atÂvarying retinal expertise levels. Journal of Current Ophthalmology, 2019, 31, 161-167.	0.3	9
922	Prefilled syringes for intravitreal drug delivery . Clinical Ophthalmology, 2019, Volume 13, 701-706.	0.9	20
923	Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid. BMC Ophthalmology, 2019, 19, 103.	0.6	6
925	How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview. Advances in Therapy, 2019, 36, 1532-1548.	1.3	18
926	Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept. American Journal of Ophthalmology, 2019, 207, 385-394.	1.7	11
927	Short-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance Study. Korean Journal of Ophthalmology: KJO, 2019, 33, 150.	0.5	7
928	Appearance of Polypoidal Lesions in Patients With Polypoidal Choroidal Vasculopathy Using Swept-Source Optical Coherence Tomographic Angiography. JAMA Ophthalmology, 2019, 137, 642.	1.4	58
929	AGE-RELATED MACULAR DEGENERATIONâ€“ASSOCIATED PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION IN THE ERA OF ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2019, 39, 1936-1944.	1.0	5
930	Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmology, 2019, 4, e000185.	0.8	12
931	Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits. Technology and Health Care, 2019, 27, 153-163.	0.5	17

#	Article	IF	Citations
932	TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 2077-2083.	1.0	17
933	Best Clinical Practice for Age-Related Macular Degeneration Imaging. Journal of Vitreoretinal Diseases, 2019, 3, 167-171.	0.2	4
934	Evaluation of Transplanted Autologous Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in Exudative Age-Related Macular Degeneration. Ophthalmology Retina, 2019, 3, 850-859.	1.2	82
935	EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDEâ€“TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2019, 39, 1953-1958.	1.0	6
936	A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand. BMC Ophthalmology, 2019, 19, 82.	0.6	9
937	Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. , 2019, 60, 1088.		26
938	Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in Japan. PLoS ONE, 2019, 14, e0213161.	1.1	3
939	Lessons Learned From Avastin and OCTâ€“The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. American Journal of Ophthalmology, 2019, 204, 26-45.	1.7	10
941	Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Scientific Reports, 2019, 9, 3301.	1.6	35
942	Refractive Error Has Minimal Influence on the Risk of Age-Related Macular Degeneration: A Mendelian Randomization Study. American Journal of Ophthalmology, 2019, 206, 87-93.	1.7	11
943	The results of aflibercept therapy as a first line treatment of age-related macular degeneration. Journal of Current Ophthalmology, 2019, 31, 66-71.	0.3	6
944	In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor. Research in Veterinary Science, 2019, 124, 233-238.	0.9	9
945	Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations. Ophthalmology and Therapy, 2019, 8, 235-249.	1.0	13
946	Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease. Ophthalmology, 2019, 126, 841-848.	2.5	61
947	ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Retina, 2019, 39, 1965-1972.	1.0	2
948	Medical Applications of iPS Cells. Current Human Cell Research and Applications, 2019, , .	0.1	0
949	Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center. Ophthalmologica, 2019, 242, 1-7.	1.0	19
950	Induced Pluripotent Stem Cell-Based Cell Therapy of theÂRetina. Current Human Cell Research and Applications, 2019, , 133-147.	0.1	0

#	Article	IF	Citations
951	A 2-Year Longitudinal Study of Normal Cone Photoreceptor Density. , 2019, 60, 1420.		11
952	Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa. International Journal of Retina and Vitreous, 2019, 5, 7.	0.9	20
953	Serum vascular endothelial growth factor changes and safety after topical antiâ€human VEGF antibody bevacizumab in healthy dogs. Veterinary Ophthalmology, 2019, 22, 600-606.	0.6	3
955	Longâ€term outcomes of switching to aflibercept for treatmentâ€resistant neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2019, 97, e706-e712.	0.6	8
956	Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration. Scientific Reports, 2019, 9, 2614.	1.6	5
957	Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 741-748.	1.0	6
958	Age-Related Macular Degeneration: Clinical Management. , 2019, , 53-66.		0
959	Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology. Pharmaceutical Research, 2019, 36, 54.	1.7	3
960	Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration. Stem Cells Translational Medicine, 2019, 8, 466-477.	1.6	60
962	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmology, 2019, 4, e000398.	0.8	85
963	Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eyeâ€drops among rats, rabbits and monkeys. Pharmacology Research and Perspectives, 2019, 7, e00545.	1.1	20
964	Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration. Expert Review of Ophthalmology, 2019, 14, 287-307.	0.3	2
965	Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization. Molecular Therapy - Methods and Clinical Development, 2019, 15, 403-417.	1.8	13
966	Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. GeroScience, 2019, 41, 813-845.	2.1	49
967	Development of Kaempferol-Loaded Gelatin Nanoparticles for the Treatment of Corneal Neovascularization in Mice. Pharmaceutics, 2019, 11, 635.	2.0	35
968	Asia-Pacific Technology and Trend Survey 2016-2017. Asia-Pacific Journal of Ophthalmology, 2019, 8, 43-54.	1.3	5
969	Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration . Clinical Ophthalmology, 2019, Volume 13, 2563-2572.	0.9	14
970	Intravitreal Injections Among Medicare Part B Beneficiaries, 2012-2016. Journal of Vitreoretinal Diseases, 2019, 3, 354-357.	0.2	1

#	Article	IF	Citations
971	Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 55-63.	2.5	113
972	Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. Clinical and Experimental Ophthalmology, 2019, 47, 240-249.	1.3	11
973	The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab. American Journal of Ophthalmology, 2019, 199, 200-208.	1.7	56
974	A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy. Ophthalmology Retina, 2019, 3, 220-229.	1.2	16
975	Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. British Journal of Ophthalmology, 2019, 103, 442-451.	2.1	29
976	Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 273-278.	1.0	7
977	Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results. Japanese Journal of Ophthalmology, 2019, 63, 90-99.	0.9	2
978	In situ chemically crosslinked injectable hydrogels for the subcutaneous delivery of trastuzumab to treat breast cancer. Acta Biomaterialia, 2019, 86, 280-290.	4.1	29
979	Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen. Ophthalmology, 2019, 126, 723-734.	2.5	222
980	Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Antiâ€“Vascular Endothelial Growth Factor Agents. Ophthalmology, 2019, 126, 735-742.	2.5	31
981	Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2019, 126, 252-260.	2.5	153
982	The Developing Regorafenib Eye drops for neovascular Ageâ€related Macular degeneration (DREAM) study: an openâ€label phase II trial. British Journal of Clinical Pharmacology, 2019, 85, 347-355.	1.1	35
984	Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease. Journal of Molecular Medicine, 2019, 97, 215-229.	1.7	42
985	OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 303-313.	1.0	8
986	MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 296-302.	1.0	6
987	EFFECT OF INTRAOCULAR PRESSUREâ€“LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. Retina, 2019, 39, 636-647.	1.0	5
988	Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. European Journal of Ophthalmology, 2020, 30, 1082-1090.	0.7	2
989	Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. European Journal of Ophthalmology, 2020, 30, 66-71.	0.7	8

#	Article	IF	Citations
990	Regenerative medicine as a novel strategy for AMD treatment: a review. Biomedical Physics and Engineering Express, 2020, 6, 012001.	0.6	2
991	Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting. European Journal of Ophthalmology, 2020, 30, 543-549.	0.7	7
992	Macular Atrophy in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 198-210.	2.5	51
993	Comparison of two different treatâ€andâ€extend protocols with aflibercept in wet ageâ€related macular degeneration. Acta Ophthalmologica, 2020, 98, 267-273.	0.6	9
994	Automated segmentation of intraretinal cystoid macular edema based on Gaussian mixture model. Journal of Innovative Optical Health Sciences, 2020, 13, .	0.5	5
995	Thirteen years of intravitreal antiâ€vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway.. Acta Ophthalmologica, 2020, 98, 774-779.	0.6	12
996	Task shifting of intraocular injections from physicians to nurses: a randomized singleâ€masked noninferiority study. Acta Ophthalmologica, 2020, 98, 139-144.	0.6	17
997	Visual Acuity Outcomes and Antiâ€“Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients. Ophthalmology Retina, 2020, 4, 19-30.	1.2	108
998	The Value of Prior Response to Antiâ€“Vascular Endothelial Growth Factor for Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 13-18.	1.2	2
999	Implication of inflammatory cytokines in the aqueous humour for management of macular diseases. Acta Ophthalmologica, 2020, 98, e309-e315.	0.6	20
1000	A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. Ophthalmology and Therapy, 2020, 9, 35-75.	1.0	5
1001	Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease. JAMA Ophthalmology, 2020, 138, 244.	1.4	54
1002	In vitro response and gene expression of human retinal MÃ¼ller cells treated with different anti-VEGF drugs. Experimental Eye Research, 2020, 191, 107903.	1.2	6
1003	Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 503-511.	1.0	35
1004	Age-Related Macular Degeneration Preferred Practice PatternÂ®. Ophthalmology, 2020, 127, P1-P65.	2.5	167
1005	SMOKING STATUS AND TREATMENT OUTCOMES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 1696-1703.	1.0	5
1006	Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. Ophthalmology Retina, 2020, 4, 403-414.	1.2	25
1007	Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 784-792.	2.5	16

#	Article	IF	Citations
1008	Noncompliance in Prospective Retina Clinical Trials: Analysis of Factors Predicting Loss to Follow-up. American Journal of Ophthalmology, 2020, 210, 86-96.	1.7	17
1009	Visual Acuity Outcomes after Antiâ€“Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 3-12.	1.2	15
1010	TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Retina, 2020, 40, 1665-1672.	1.0	17
1011	Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration. Journal of International Medical Research, 2020, 48, 030006052093161.	0.4	6
1012	Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices. Frontiers in Bioengineering and Biotechnology, 2020, 8, 549089.	2.0	7
1013	Novel Programmed Cell Death as Therapeutic Targets in Age-Related Macular Degeneration?. International Journal of Molecular Sciences, 2020, 21, 7279.	1.8	32
1014	Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration. , 2020, , .		1
1015	Office Examinationsâ€“Directed Treatment Paradigms Reduce Travel Burden, Decrease Treatment Cost, and Improve Quality-Adjusted Life-Years for Patients With Exudative Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor Therapy. Journal of Vitreoretinal Diseases, 2020, 4, 472-478.	0.2	1
1016	Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial. Journal of Ophthalmology, 2020, 2020, 1-13.	0.6	5
1017	PREDICTORS OF RECURRENT EXUDATION IN CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION DURING A TREATMENT-FREE PERIOD. Retina, 2020, 40, 2158-2165.	1.0	7
1018	TriPla Regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 â€œeraâ€• European Journal of Ophthalmology, 2020, 31, 112067212096344.	0.7	8
1019	Ten-year survival trends of neovascular age-related macular degeneration at first presentation. British Journal of Ophthalmology, 2021, 105, 1688-1695.	2.1	9
1020	Randomized Safety and Feasibility Trial of Ultra-Rapid Cooling Anesthesia for Intravitreal Injections. Ophthalmology Retina, 2020, 4, 979-986.	1.2	4
1021	Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Antiâ€“Vascular Endothelial Growth Factor Injections. Ophthalmology Retina, 2020, 4, 1047-1053.	1.2	10
1022	Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 871-880.	1.2	20
1023	Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye, 2020, 35, 2793-2801.	1.1	16
1024	Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?. Retina, 2020, 40, 1451-1455.	1.0	11
1025	Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease. Topics in Medicinal Chemistry, 2020, , 125-160.	0.4	3

#	Article	IF	Citations
1026	Ageâ€related macular degeneration (<scp>AMD</scp>): More than meets the eye. The role of multimodal imaging in today's management of <scp>AMD</scp>â€”A review. Clinical and Experimental Ophthalmology, 2020, 48, 983-995.	1.3	26
1027	Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy. British Journal of Ophthalmology, 2022, 106, 113-120.	2.1	27
1030	Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232095334.	1.1	12
1031	Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study. Ophthalmology and Therapy, 2020, 9, 993-1002.	1.0	2
1032	Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany. Journal of Ophthalmology, 2020, 2020, 1-11.	0.6	4
1033	NEI-Supported Age-Related Macular Degeneration Research: Past, Present, and Future. Translational Vision Science and Technology, 2020, 9, 49.	1.1	7
1034	Imaging of Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Inhibitors by Optical Coherence Tomography Angiography in a Rat Model. Translational Vision Science and Technology, 2020, 9, 29.	1.1	0
1035	Treating Neovascular Age-Related Macular Degenerationâ€”So Much More to Learn. JAMA Ophthalmology, 2020, 138, 1051.	1.4	1
1036	Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Antiâ€“Vascular Endothelial Growth Factor Agents. JAMA Ophthalmology, 2020, 138, 1043.	1.4	77
1037	Clinical manifestations of intravitreal bortezomib injection. American Journal of Ophthalmology Case Reports, 2020, 20, 100968.	0.4	1
1038	Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. International Journal of Molecular Sciences, 2020, 21, 9251.	1.8	6
1039	Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study . Clinical Ophthalmology, 2020, Volume 14, 3599-3610.	0.9	2
1040	Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naÃ¯ve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!. Journal Francais D'Ophtalmologie, 2020, 43, 761-769.	0.2	5
1041	Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis. European Journal of Ophthalmology, 2021, 31, 2496-2504.	0.7	10
1042	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences, 2020, 21, 8242.	1.8	82
1043	Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors. Scientific Reports, 2020, 10, 8036.	1.6	20
1044	Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. British Journal of Ophthalmology, 2020, 104, 672-677.	2.1	14
1045	Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. The Cochrane Library, 2020, 2020, CD012208.	1.5	52

#	Article	IF	Citations
1046	Design, implementation, and evaluation of a nurse-led intravitreal injection programme for retinal diseases in Singapore. Eye, 2020, 34, 2123-2130.	1.1	5
1047	Definition of indicators of appropriateness in the management of neovascular age-related macular degeneration: An expert opinion. European Journal of Ophthalmology, 2020, 30, 795-804.	0.7	2
1048	Management and Outcomes for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 1179-1188.	2.5	29
1049	Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration. PLoS ONE, 2020, 15, e0232353.	1.1	13
1051	Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen. Ophthalmology, 2020, 127, 1663-1673.	2.5	23
1052	Lutein Supplementation for Eye Diseases. Nutrients, 2020, 12, 1721.	1.7	64
1053	Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2020, 218, 225-241.	1.7	22
1054	Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 393-403.	0.6	11
1055	Triptolide attenuates laser-induced choroidal neovascularization via M2 macrophage in a mouse model. Biomedicine and Pharmacotherapy, 2020, 129, 110312.	2.5	8
1056	End-to-End Deep Learning Model for Predicting Treatment Requirements in Neovascular AMD From Longitudinal Retinal OCT Imaging. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 3456-3465.	3.9	35
1057	SAVING SIGHT IN NEOVASCULAR AMD. Retina, 2020, 40, S1-S12.	1.0	0
1058	Survey of Intravitreal Injection Practice Patterns Among Retina Specialists. Journal of Vitreoretinal Diseases, 2020, 4, 306-311.	0.2	1
1059	Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan. Journal of Ophthalmology, 2020, 2020, 1-8.	0.6	5
1060	Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Canadian Journal of Ophthalmology, 2020, 55, 286-292.	0.4	14
1061	Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment . Patient Preference and Adherence, 2020, Volume 14, 553-567.	0.8	17
1062	RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY. Retina, 2020, 40, 679-685.	1.0	11
1064	Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study . Clinical Ophthalmology, 2020, Volume 14, 1473-1481.	0.9	4
1065	Long-Term Visual/Anatomic Outcome in Patients with Fovea-Involving Fibrovascular Pigment Epithelium Detachment Presenting Choroidal Neovascularization on Optical Coherence Tomography Angiography. Journal of Clinical Medicine, 2020, 9, 1863.	1.0	5

#	Article	IF	Citations
1066	Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. International Ophthalmology, 2020, 40, 3067-3075.	0.6	5
1067	Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update. Molecular Therapy, 2020, 28, 2120-2138.	3.7	38
1068	Surgical management of submacular hemorrhage due to n-AMD: a comparison of three surgical methods. International Journal of Retina and Vitreous, 2020, 6, 27.	0.9	11
1069	Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice. International Journal of Retina and Vitreous, 2020, 6, 9.	0.9	3
1070	ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD). British Journal of Ophthalmology, 2020, 104, bjophthalmol-2019-315717.	2.1	11
1071	Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 253-266.	0.5	13
1072	Diabetic Retinopathy Screening Using a Gold Nanoparticleâ€“Based Paper Strip Assay for the At-Home Detection of the Urinary Biomarker 8-Hydroxy-2â€²-Deoxyguanosine. American Journal of Ophthalmology, 2020, 213, 306-319.	1.7	15
1073	Vascular density in age-related macular degeneration after one year of antiVEGF treatment with treat-and-extend and fixed regimens. PLoS ONE, 2020, 15, e0229388.	1.1	5
1074	A profile of circulating vascular progenitor cells in human neovascular age-related macular degeneration. PLoS ONE, 2020, 15, e0229504.	1.1	1
1075	The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Eye, 2020, 34, 2257-2263.	1.1	9
1076	Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2020, 2020, 1-7.	0.6	3
1077	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. BMC Ophthalmology, 2020, 20, 21.	0.6	1
1078	Near-Infrared Reflectance Imaging for Quantification of Atrophy Associated with Age-Related Macular Degeneration. American Journal of Ophthalmology, 2020, 212, 169-174.	1.7	14
1079	Anti-angiogenesis by dual action of R5K peptide conjugated itraconazole nanoparticles. AAPS PharmSciTech, 2020, 21, 74.	1.5	16
1080	Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5. JAMA Ophthalmology, 2020, 138, 276.	1.4	5
1081	Therapeutic effect against retinal neovascularization in a mouse model of oxygen-induced retinopathy: bone marrow-derived mesenchymal stem cells versus Conbercept. BMC Ophthalmology, 2020, 20, 7.	0.6	12
1082	Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2020, 138, 237.	1.4	40
1083	Association Between Visit Adherence and Visual Acuity in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2020, 138, 242.	1.4	2

#	Article	IF	Citations
1084	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration â€“ results from the randomized, phase IIIb OCTAVE study. BMC Ophthalmology, 2020, 20, 18.	0.6	8
1085	Comparison of Age-Related Macular Degeneration Treatments Trials 2: Introducing Comparative Effectiveness Research. Ophthalmology, 2020, 127, S133-S134.	2.5	2
1086	Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. JAMA Ophthalmology, 2020, 138, 510.	1.4	12
1087	Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2020, 138, 560.	1.4	10
1088	Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity. JAMA Ophthalmology, 2020, 138, 610.	1.4	10
1089	Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1405-1410.	1.0	1
1090	Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2ÂYears: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison. Advances in Therapy, 2020, 37, 2184-2198.	1.3	28
1091	Comparison of Two Different Treat-and-Extend Protocols with Aflibercept in Wet Age-Related Macular Degeneration: Two-Year Results. Advances in Therapy, 2020, 37, 2256-2266.	1.3	6
1092	Application of Automated Quantification of Fluid Volumes to Antiâ€“VEGF Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 1211-1219.	2.5	89
1093	Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. British Journal of Ophthalmology, 2020, 104, 58-63.	2.1	9
1094	Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. British Journal of Ophthalmology, 2020, 104, 1052-1056.	2.1	20
1095	Regional differences in the global burden of age-related macular degeneration. BMC Public Health, 2020, 20, 410.	1.2	30
1096	Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT. Ophthalmology, 2021, 128, 100-109.	2.5	53
1097	Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors. European Journal of Ophthalmology, 2021, 31, 521-528.	0.7	2
1098	Home Monitoring of Age-Related Macular Degeneration. Ophthalmology Retina, 2021, 5, 348-356.	1.2	19
1099	Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmologe, 2021, 118, 31-39.	0.4	8
1100	Profiling neovascular ageâ€related macular degeneration choroidal neovascularization lesion response to antiâ€vascular endothelial growth factor therapy using SSOCTA. Acta Ophthalmologica, 2021, 99, e240-e246.	0.6	11
1101	A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. American Journal of Ophthalmology, 2021, 223, 405-429.	1.7	12

#	Article	IF	Citations
1102	Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Progress in Retinal and Eye Research, 2021, 82, 100906.	7.3	133
1103	Characterization of tryptophanâ€containing dipeptides for antiâ€angiogenic effects. Acta Physiologica, 2021, 231, e13556.	1.8	2
1104	Long-term Antiâ€"Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study. Ophthalmology Retina, 2021, 5, 511-518.	1.2	10
1105	Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular ageâ€"related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1463-1470.	1.0	10
1106	Correlation of Retinal Thickness and Swept-Source Optical Coherence Tomography Angiography Derived Vascular Changes in Patients with Neovascular Age-Related Macular Degeneration. Current Eye Research, 2021, 46, 1002-1009.	0.7	9
1107	Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials. American Journal of Ophthalmology, 2021, 223, 338-347.	1.7	9
1108	Estudio del fluido tomogrÃ¡fico y concordancia en su detecciÃ³n entre mÃ©dicos residentes en pacientes nÃ¡ive con degeneraciÃ³n macular asociada a la edad (DMAE) neovascular. Archivos De La Sociedad Espanola De Oftalmologia, 2021, 96, 236-241.	0.1	0
1109	The influence of dead spaces and the designs of injectors on the amount of drug dose in intra-vitreal injection. European Journal of Ophthalmology, 2021, 31, 592-599.	0.7	4
1110	The influence of hyperglycemia on the safety of ultrasound in retinal pigment epithelial cells. Cell Biology International, 2021, 45, 558-568.	1.4	3
1111	Differential effects of risuteganib and bevacizumab on AMD cybrid cells. Experimental Eye Research, 2021, 203, 108287.	1.2	8
1112	C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration. Ophthalmology, 2021, 128, 576-586.	2.5	230
1113	Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. European Journal of Ophthalmology, 2021, 31, 144-148.	0.7	0
1115	Pharmacotherapy of Age-Related Macular Degeneration. , 2021, , 1-26.		0
1116	Efficacy and safety of different agents, dosages and strategies of antiâ€vascular endothelial growth factor treatment for neovascular ageâ€related macular degeneration: a network metaâ€analysis of randomized controlled trials. Acta Ophthalmologica, 2021, 99, e1041-e1050.	0.6	4
1117	Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial. Trials, 2021, 22, 69.	0.7	2
1118	Ocular Imaging for Enhancing the Understanding, Assessment, and Management of Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2021, 1256, 33-66.	0.8	2
1119	Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy. International Journal of Molecular Sciences, 2021, 22, 1170.	1.8	40
1120	A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies. Pharmaceuticals, 2021, 14, 50.	1.7	9

#	Article	IF	Citations
1121	Choroidal Neovascularization. , 2021, , 271-293.		0
1122	Investigating the effects of carvacrol in rats using oxygen-induced retinopathy model. Indian Journal of Ophthalmology, 2021, 69, 1219.	0.5	2
1123	Retina. , 2021, , 89-114.		0
1125	Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials. BMJ Open, 2021, 11, e040906.	0.8	3
1126	Patterns and Predictors of Successful Treatment Discontinuation in Retinal Vein Occlusions With Macular Edema in the Real World. Ophthalmic Surgery Lasers and Imaging Retina, 2021, 52, 84-92.	0.4	3
1127	Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye, 2021, 35, 1305-1316.	1.1	72
1128	Application of Deep Learning for Diagnosing, Classifying, and Treating Age-Related Macular Degeneration. Seminars in Ophthalmology, 2021, 36, 198-204.	0.8	6
1129	Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study. International Journal of Retina and Vitreous, 2021, 7, 11.	0.9	6
1130	Long-Term Stability of Anti-Vascular Endothelial Growth Factor (a-VEGF) Biologics Under Physiologically Relevant Conditions and Its Impact on the Development of Long-Acting Delivery Systems. Journal of Pharmaceutical Sciences, 2021, 110, 860-870.	1.6	8
1131	Changes in the Foveal Avascular Zone Area and Retinal Vessel Density after Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. Seminars in Ophthalmology, 2021, 36, 110-114.	0.8	3
1132	Ziv-aflibercept for Better Regulating Neovascular Age-Related Macular Degeneration (ZEBRA): A Prospective, Randomized Trial. Seminars in Ophthalmology, 2021, 36, 28-34.	0.8	1
1133	COCO/DAND5 inhibits developmental and pathological ocular angiogenesis. EMBO Molecular Medicine, 2021, 13, e12005.	3.3	5
1134	Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study. PLoS ONE, 2021, 16, e0247161.	1.1	34
1135	Drug-related adverse effects of antivascular endothelial growth factor agents. Current Opinion in Ophthalmology, 2021, 32, 191-197.	1.3	13
1136	Application of Clinical Trial Results to Clinical Practice: Some Reminders and Considerations. Ophthalmology Retina, 2021, 5, 221-223.	1.2	1
1137	Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. American Journal of Pathology, 2021, 191, 418-424.	1.9	9
1138	Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. Pharmaceutics, 2021, 13, 322.	2.0	12
1139	Express Medicineâ€"Potential for Home-Based Medical Care. JAMA Ophthalmology, 2021, 139, 269.	1.4	2

#	Article	IF	Citations
1140	High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration. Scientific Reports, 2021, 11, 6816.	1.6	5
1141	An Overview of Age-Related Macular Degeneration: Clinical, Pre-Clinical Animal Models and Bidirectional Translation. , 0, , .		6
1142	MicroRNAs and the HIF/VEGF axis in ocular neovascular diseases. Acta Ophthalmologica, 2021, 99, e1255-e1262.	0.6	17
1143	Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. BioDrugs, 2021, 35, 303-323.	2.2	3
1144	Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion. Ophthalmology and Therapy, 2021, 10, 231-243.	1.0	1
1145	Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration. Frontiers in Pharmacology, 2021, 12, 656774.	1.6	7
1146	Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases. Ophthalmology and Therapy, 2021, 10, 337-348.	1.0	14
1147	Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmology, 2021, 6, e000669.	0.8	9
1148	Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2021, 224, 267-281.	1.7	33
1149	Curcuma-Based Nutritional Supplement in Patients with Neovascular Age-Related Macular Degeneration. Journal of Medicinal Food, 2021, 24, 1191-1196.	0.8	7
1150	Nanotechnology: revolutionizing the delivery of drugs to treat age-related macular degeneration. Expert Opinion on Drug Delivery, 2021, 18, 1131-1149.	2.4	7
1151	PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections. Journal of Ophthalmic and Vision Research, 2021, 16, 178-186.	0.7	3
1152	Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina. Cutaneous and Ocular Toxicology, 2021, 40, 135-139.	0.5	5
1153	Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. International Journal of Retina and Vitreous, 2021, 7, 26.	0.9	6
1154	Quantifying Conflict of Interest in the Choice of Anti-VEGF Agents. Clinical Ophthalmology, 2021, Volume 15, 1403-1408.	0.9	4
1155	Echinomycin mitigates ocular angiogenesis by transcriptional inhibition of the hypoxia-inducible factor-1. Experimental Eye Research, 2021, 206, 108518.	1.2	7
1156	Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Eye, 2022, 36, 862-868.	1.1	10
1157	Resident physician concordance in tomographic fluid detection in nÃive patients with neovascular age-related macular degeneration (AMD). Archivos De La Sociedad Espanola De Oftalmologia, 2021, 96, 236-241.	0.1	0

#	Article	IF	Citations
1158	Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?. BMC Ophthalmology, 2021, 21, 243.	0.6	2
1159	Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. British Journal of Ophthalmology, 2022, 106, 1561-1566.	2.1	8
1160	Association between retinal thickness variation and visual acuity change in neovascular ageâ€related macular degeneration. Clinical and Experimental Ophthalmology, 2021, 49, 430-438.	1.3	3
1161	Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. International Journal of Retina and Vitreous, 2021, 7, 37.	0.9	53
1162	A 5-Year Analysis of Physician-Industry Interactions, Physician Gender, and Anti-VEGF Use in US Ophthalmologists. Seminars in Ophthalmology, 2021, 36, 804-811.	0.8	5
1163	An insight on the anatomical and functional consequences of aflibercept therapy in age-related macular degeneration. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102307.	1.3	0
1164	Quantification of Key Retinal Features in Early and Late Age-Related Macular Degeneration Using Deep Learning. American Journal of Ophthalmology, 2021, 226, 1-12.	1.7	32
1165	Prospective, Longitudinal Pilot Study. Ophthalmology Science, 2021, 1, 100034.	1.0	27
1166	Exploration of the Effect and Mechanism of Fructus Lycii, Rehmanniae Radix Praeparata, and Paeonia lactiflora in the Treatment of AMD Based on Network Pharmacology and in vitro Experimental Verification. Drug Design, Development and Therapy, 2021, Volume 15, 2831-2842.	2.0	7
1167	Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer. Cells, 2021, 10, 1617.	1.8	11
1168	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. Expert Review of Ophthalmology, 2021, 16, 267-286.	0.3	0
1169	Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 743-752.	0.5	9
1170	Assessment of efficacy and safety of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion. Indian Journal of Clinical and Experimental Ophthalmology, 2021, 7, 376-380.	0.1	0
1171	AI-based monitoring of retinal fluid in disease activity and under therapy. Progress in Retinal and Eye Research, 2022, 86, 100972.	7.3	30
1172	Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells. Current Eye Research, 2021, , 1-8.	0.7	3
1173	Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment, 2021, 25, 1-196.	1.3	10
1174	A novel and biocompatible nanofiber of VEGF peptide for enhanced corneal neovascularization suppression. Chemical Engineering Journal, 2021, 416, 129081.	6.6	7
1175	One-year Outcomes of a Treat-and-extend of Ranibizumab for Naive Exudative Age-related Macular Degeneration: Retrospective Analysis. Journal of Korean Ophthalmological Society, 2021, 62, 939-947.	0.0	0

#	Article	IF	Citations
1176	Incidence of ocular hypertension in patients receiving intravitreal anti-VEGF injections: comparing filtered drug in plastic silicone-free syringes to nonfiltered drug in silicone-lined insulin plastic syringes. Canadian Journal of Ophthalmology, 2021, , .	0.4	0
1177	THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2022, 42, 95-106.	1.0	6
1178	The 100 most-cited papers on age-related macular degeneration: a bibliographic perspective. BMJ Open Ophthalmology, 2021, 6, e000823.	0.8	4
1179	Reduction of choroidal neovascularization via cleavable VEGF antibodies conjugated to exosomes derived from regulatory T cells. Nature Biomedical Engineering, 2021, 5, 968-982.	11.6	52
1180	Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3665-3673.	1.0	5
1181	The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results. Ophthalmology and Therapy, 2021, 10, 935-945.	1.0	14
1182	Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients. BMC Ophthalmology, 2021, 21, 294.	0.6	5
1183	Genetic associations of antiâ€vascular endothelial growth factor therapy response in ageâ€related macular degeneration: a systematic review and metaâ€analysis. Acta Ophthalmologica, 2022, 100, .	0.6	12
1184	Durability of antiâ€vascular endothelial growth factor agents in neovascular ageâ€related macular degeneration. Clinical and Experimental Ophthalmology, 2021, 49, 540-541.	1.3	0
1185	Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade. Ophthalmology Retina, 2021, 5, e11-e22.	1.2	9
1186	Short-Term Outcomes following â€œSwitchingâ€•to Monthly Ranibizumab in Neovascular Age-Related Macular Degeneration Showing Insufficient Response to Bimonthly Aflibercept. Journal of Ophthalmology, 2021, 2021, 1-8.	0.6	3
1187	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration â€“ Current Perspectives. Clinical Ophthalmology, 2021, Volume 15, 3351-3367.	0.9	15
1188	Prevention of vision-threatening complications in diabetic retinopathy. Current Opinion in Ophthalmology, 2021, Publish Ahead of Print, 590-598.	1.3	5
1189	Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. BMC Ophthalmology, 2021, 21, 300.	0.6	13
1190	IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2022, 42, 589-606.	1.0	20
1191	Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2022, 6, 205-212.	1.2	3
1193	Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study. British Journal of Ophthalmology, 2023, 107, 96-101.	2.1	5
1194	Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 83-92.	1.0	3

#	Article	IF	Citations
1195	Age-Related Macular Degeneration. New England Journal of Medicine, 2021, 385, 539-547.	13.9	65
1196	Intraretinal, sub-retinal, and sub-retinal pigmented epithelium fluid in non-exudative age-related macular degeneration: follow-up with OCT imaging. European Journal of Ophthalmology, 2022, 32, 2419-2426.	0.7	4
1197	Review of the management of sight-threatening diabetic retinopathy during pregnancy. World Journal of Diabetes, 2021, 12, 1386-1400.	1.3	4
1198	Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Japanese Journal of Ophthalmology, 2021, 65, 741-760.	0.9	7
1199	Outcomes of Abrupt Switch to Bevacizumab of Patients Undergoing Aflibercept Intravitreal Injections for Neovascular Age-Related Macular Degeneration in a Tertiary Center in Lombardy, Italy: A Real-Life Retrospective Analysis. Journal of Ophthalmology, 2021, 2021, 1-4.	0.6	1
1200	SINGLE INJECTION RESPONSE TO ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION. Retina, 2021, 41, 1901-1910.	1.0	4
1201	Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clinical Therapeutics, 2021, 43, 1792-1818.	1.1	38
1202	Use of Bevacizumab Injections in Medicare Fee For Service in the IRISÂ® Registry. Ophthalmology Retina, 2021, 5, 935-936.	1.2	2
1203	Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series. Veterinary Ophthalmology, 2021, 24, 554-568.	0.6	3
1204	ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with Age-Related Macular Degeneration and Anti-VEGF Treatment. Medicina (Lithuania), 2021, 57, 974.	0.8	2
1205	Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1260-1272.	0.5	6
1206	Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. Pharmaceutics, 2021, 13, 1491.	2.0	4
1207	Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. Journal of Experimental Pharmacology, 2021, Volume 13, 905-912.	1.5	37
1208	Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study. Journal of the Nepal Medical Association, 2021, 59, 858-861.	0.1	0
1209	Protective chromosome 1q32 haplotypes mitigate risk for age-related macular degeneration associated with the CFH-CFHR5 and ARMS2/HTRA1 loci. Human Genomics, 2021, 15, 60.	1.4	17
1210	Pipeline therapies for neovascular age related macular degeneration. International Journal of Retina and Vitreous, 2021, 7, 55.	0.9	21
1211	Photo-Responsive Hydrogel Mns with Interlocking Control for Easy Extraction in Sustained Ocular Drug Delivery. Journal of Engineering and Science in Medical Diagnostics and Therapy, 2021, , .	0.3	3
1212	Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology Retina, 2021, 5, 962-974.	1.2	9

#	Article	IF	Citations
1213	Crosstalk Between RPE Cells and Choroidal Endothelial Cells via the ANXA1/FPR2/SHP2/NLRP3 Inflammasome/Pyroptosis Axis Promotes Choroidal Neovascularization. Inflammation, 2022, 45, 414-427.	1.7	10
1214	Management of age-related macular degeneration. , 2022, , 217-231.		2
1215	Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2021, 5, 23-31.	1.2	8
1216	ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR DOSING AND EXPECTED ACUITY OUTCOME AT 1 YEAR. Retina, 2021, 41, 1153-1163.	1.0	7
1217	Current Management of Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2021, 1256, 295-314.	0.8	6
1218	Retinal Vascular Disease. , 2021, , 89-123.		0
1219	Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2021, 244, 265-280.	1.0	4
1220	Digital Technology for AMD Management in the Post-COVID-19 New Normal. Asia-Pacific Journal of Ophthalmology, 2021, 10, 39-48.	1.3	18
1221	Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 189-194.	0.9	1
1222	Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs. Journal of Law, Medicine and Ethics, 2021, 49, 19-24.	0.4	1
1223	Clinical Trials of Retinal Cell Therapy. Pancreatic Islet Biology, 2019, , 245-265.	0.1	2
1224	Age-Related Macular Degeneration and Vision Impairment. , 2016, , 471-507.		1
1226	Angiogenesis-Based Therapies for Eye Diseases. , 2017, , 259-297.		2
1227	Is This a 737 Max Moment for Brolucizumab?. American Journal of Ophthalmology, 2020, 216, A7-A8.	1.7	13
1228	Preclinical challenges for developing long acting intravitreal medicines. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 130-149.	2.0	21
1229	Dose-Response Relationship between Intravitreal Injections and Retinal Nerve Fiber Layer Thinning in Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 5, 648-654.	1.2	10
1230	Evaluation of a Self-Imaging SD-OCT System for Remote Monitoring of Patients with Neovascular Age Related Macular Degeneration. Klinische Monatsblatter Fur Augenheilkunde, 2020, 237, 1410-1418.	0.3	17
1231	BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. Retina, 2021, 41, 125-134.	1.0	1

#	Article	IF	Citations
1232	CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE. Retina, 2021, 41, 581-587.	1.0	19
1233	Progression of macular atrophy in patients undergoing antiâ€vascular endothelial growth factor therapy for neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2021, 99, e540-e546.	0.6	11
1234	Realâ€world treatment outcomes of neovascular Ageâ€related Macular Degeneration in the Netherlands. Acta Ophthalmologica, 2021, 99, e884-e892.	0.6	8
1235	Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD. British Journal of Ophthalmology, 2020, , bjophthalmol-2020-317563.	2.1	2
1236	Recent developments in the treatment of age-related macular degeneration. Journal of Clinical Investigation, 2014, 124, 1430-1438.	3.9	171
1237	Advances in the management of macular degeneration. F1000prime Reports, 2014, 6, 29.	5.9	33
1238	A Prospective Study of Treatment Patterns and 1-Year Outcome of Asian Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. PLoS ONE, 2014, 9, e101057.	1.1	47
1239	Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment. PLoS ONE, 2014, 9, e101072.	1.1	43
1240	Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2014, 9, e101253.	1.1	9
1241	Combined Intravitreal Anti-VEGF and Photodynamic Therapy versus Photodynamic Monotherapy for Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis of Comparative Studies. PLoS ONE, 2014, 9, e110667.	1.1	47
1242	Analysis of Macular Drusen and Blood Test Results in 945 Macaca fascicularis. PLoS ONE, 2016, 11, e0164899.	1.1	6
1245	Infectious and sterile endophthalmitis after intravitreal injections: differential diagnosis, prevention, treatment. Ophthalmology Journal, 2017, 10, 62-69.	0.1	5
1246	Fixed bimonthly aflibercept in naÃ¯ve and switched neovascular age-related macular degeneration patients: one year outcomes. International Journal of Ophthalmology, 2016, 9, 1156-62.	0.5	7
1247	Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. International Journal of Ophthalmology, 2017, 10, 81-90.	0.5	18
1248	Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration . Biologics: Targets and Therapy, 2020, Volume 14, 83-94.	3.0	17
1249	Angiographic results of retinal-retinal anastomosis and retinal-choroidal anastomosis after treatments in eyes with retinal angiomatous proliferation. Clinical Ophthalmology, 2012, 6, 1385.	0.9	3
1250	Macular edema in the era of spectral-domain optical coherence tomography. Clinical Ophthalmology, 2013, 7, 2085.	0.9	10
1251	Aflibercept for the therapy of retinal diseases. A review of clinical studies. Rossiiskii Oftal'mologicheskii Zhurnal, 2017, 10, 103-111.	0.1	13

#	Article	IF	Citations
1252	Modeling the atrophy of retinal pigment epithelium. Rossiiskii Oftal'mologicheskii Zhurnal, 2020, 13, 58-63.	0.1	8
1253	Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration. Current Pharmaceutical Design, 2019, 24, 4860-4863.	0.9	8
1254	The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema. Current Pharmaceutical Design, 2019, 24, 4896-4902.	0.9	29
1255	Glaucoma Pathogenesis and Neurotrophins: Focus on the Molecular and Genetic Basis for Therapeutic Prospects. Current Neuropharmacology, 2018, 16, 1018-1035.	1.4	66
1256	The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration. Romanian Journal of Ophthalmology, 2019, 63, 238-244.	0.4	4
1257	Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-254.	1.3	17
1258	Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-248.	1.3	53
1259	The impact of the National Institute for Health Research Health Technology Assessment programme, 2003â€“13: a multimethod evaluation. Health Technology Assessment, 2015, 19, 1-292.	1.3	22
1260	A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technology Assessment, 2015, 19, 1-298.	1.3	62
1261	The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial. Health Technology Assessment, 2016, 20, 1-120.	1.3	9
1262	Changes in the Ganglion Cell-inner Plexiform Layer after Consecutive Intravitreal Injections of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration Patients. Korean Journal of Ophthalmology: KJO, 2020, 34, 11.	0.5	9
1263	Bromodomain Inhibitors in Degenerative Eye Disease; An Alternative to VEGF Inhibitors in Macular Degeneration?. World Journal of Ophthalmology & Vision Research, 2020, 3, .	0.1	1
1264	Influence of unilateral intravitreal bevacizumab injection on the incidence of symptomatic choroidal neovascularization in the fellow eye in patients with neovascular ageâ€‘related macular degeneration (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	0.8	5
1265	SAVE (Super-dose Anti-VEGF) Trial: 2.0 mg Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration: 1-Year Results. Ophthalmic Surgery Lasers and Imaging Retina, 2013, 44, 121-126.	0.4	25
1266	Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 143-149.	0.4	173
1267	Intravitreal Bevacizumab and Aflibercept for the Treatment of Exudative Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 275-281.	0.4	7
1268	Clinical Monitoring of Patients With Age-Related Macular Degeneration Treated With Intravitreal Bevacizumab or Ranibizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 285-291.	0.4	11
1269	Response to Aflibercept in Patients With Persistent Exudation Despite Prior Treatment With Bevacizumab or Ranibizumab for Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 394-397.	0.4	12

#	Article	IF	Citations
1270	Ultrahigh-Speed Swept-Source OCT Angiography in Exudative AMD. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 496-505.	0.4	206
1271	Cost Comparison of Intravitreal Aflibercept With Bevacizumab and Ranibizumab for the Treatment of Wet Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 62-66.	0.4	15
1272	Comparing aflibercept, bevacizumab, and ranibizumab for DME: Analysis of DRCR Protocol T. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 302-305.	0.4	12
1273	Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 523-530.	0.4	37
1274	Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 542-549.	0.4	5
1275	Evaluating Efficacy of Aflibercept in Refractory Exudative Age-Related Macular Degeneration With OCT Segmentation Volumetric Analysis. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 245-251.	0.4	4
1276	Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 555-562.	0.4	8
1277	Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 428-431.	0.4	4
1278	36-Month Evaluation of Intravitreous Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 179-185.	0.4	2
1279	Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 913-917.	0.4	11
1280	Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes: An Analysis of the IRIS Registry. Ophthalmic Surgery Lasers and Imaging Retina, 2020, 51, 633-639.	0.4	16
1281	Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. International Journal of Ophthalmology, 2013, 6, 169-73.	0.5	10
1282	Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. International Journal of Ophthalmology, 2013, 6, 327-30.	0.5	5
1283	Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. International Journal of Ophthalmology, 2014, 7, 86-91.	0.5	21
1284	Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results. Indian Journal of Ophthalmology, 2014, 62, 554.	0.5	5
1285	Cost-effectiveness of anti-oxidant vitamins plus zinc treatment to prevent the progression of intermediate age-related macular degeneration. A Singapore perspective. Indian Journal of Ophthalmology, 2015, 63, 516.	0.5	4
1286	Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian Journal of Ophthalmology, 2016, 64, 14.	0.5	20
1287	Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. Oman Journal of Ophthalmology, 2016, 9, 87.	0.2	5

#	Article	IF	Citations
1288	Clinical trials in branch retinal vein occlusion. Middle East African Journal of Ophthalmology, 2016, 23, 38.	0.5	6
1289	Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials. Middle East African Journal of Ophthalmology, 2016, 23, 27.	0.5	24
1290	Intravitreal topotecan inhibits laser-induced choroidal neovascularization in a rat model. Journal of Ophthalmic and Vision Research, 2015, 10, 295.	0.7	4
1291	Stenotrophomonas maltophilia: An emerging entity for cluster endophthalmitis. Indian Journal of Ophthalmology, 2017, 65, 1166.	0.5	11
1292	Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline. Journal of Ophthalmic and Vision Research, 2018, 13, 158.	0.7	23
1293	Current and Potential Therapies for Ocular Neovascular Diseases. Clinical & Experimental Pharmacology, 2013, 03, .	0.3	2
1294	Ranibizumab in diabetic macular edema. World Journal of Diabetes, 2013, 4, 310.	1.3	20
1295	Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration. TÃ¼rk Oftalmoloji Dergisi, 2019, 49, 258-269.	0.4	3
1296	Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: its prevalence and case reports. Digital Journal of Ophthalmology: DJO, 2015, 21, 1-7.	0.2	27
1297	Aqueous humor levels of vascular endothelial growth factor and stromal cell-derived factor-1Î± in age-related macular degeneration. Beyoglu Eye Journal, 2021, 6, 298-303.	0.1	0
1298	Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1083-1095.	1.0	1
1299	Novel metrics for evaluating decision making in a â€˜Treat and Extendâ€™ regimen for neovascular age related macular degeneration. Eye, 2021, , .	1.1	0
1300	Extract of Moutan radicis cortex and Cinnamomi ramulus ameliorates laser-induced choroidal neovascularization in Brown-Norway rats. Phytomedicine, 2022, 94, 153794.	2.3	2
1301	Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. Ophthalmologica, 2022, 245, 204-217.	1.0	16
1302	Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: Rapid distribution throughout the posterior segment. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 200-210.	2.0	5
1303	Uncovering of intraspecies macular heterogeneity in cynomolgus monkeys using hybrid machine learning optical coherence tomography image segmentation. Scientific Reports, 2021, 11, 20647.	1.6	4
1304	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab. Clinical Ophthalmology, 2021, Volume 15, 4073-4079.	0.9	6
1305	Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. BioDrugs, 2021, 35, 673-692.	2.2	19

#	Article	IF	Citations
1306	Perspectives on remote patient monitoring with self-operated OCT for management of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 0, , 1-5.	0.3	0
1307	Pro-inflammatory activation changes intracellular transport of bevacizumab in the retinal pigment epithelium in vitro. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 857-872.	1.0	2
1308	Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial. American Journal of Ophthalmology, 2022, 236, 89-98.	1.7	7
1309	To Compare Photodynamic Therapy with Ranibizumab vs Photodynamic Therapy with Pegaptanib for Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration. World Journal of Retina and Vitreous, 2012, 2, 23-27.	0.0	0
1310	Modalidades de Tratamiento de la DegeneraciÃ³n Macular Asociada a la Edad. Highlights of Ophthalmology, 2013, 41, 2-4.	0.0	0
1311	Neue Arzneimittel 2012. , 2013, , 47-120.		1
1312	Neovascular Age-Related Macular Degeneration: Rationale for Current Treatment Guidelines. Essentials in Ophthalmology, 2013, , 107-125.	0.0	0
1313	Ophthalmika. , 2013, , 765-792.		0
1314	Reliable Therapeutic Modalities To Treat Age-Related Macular Degeneration. Highlights of Ophthalmology, 2013, 41, 2-4.	0.0	0
1315	Choroidal Neovascularization. , 2014, , 211-230.		0
1317	Ophthalmika. , 2014, , 861-890.		0
1318	Present and Possible Therapies for Age-Related Macular Degeneration. Highlights of Ophthalmology, 2014, 43, 13-17.	0.0	0
1319	Results of Lucentis use as a routine practice in wet age-related macular degeneration patients. Ophthalmology Journal, 2014, 7, 47-57.	0.1	1
1320	Neovascular AMD With Marked Macular Fluid and Rapid Response to Anti-VEGF Therapy. Ophthalmic Surgery Lasers and Imaging Retina, 2014, 45, 175-178.	0.4	0
1321	Intravitreal Bevacizumab Followed by Ranibizumab for Neovascular Age Related Macular DegeneratÄ±on. International Journal of Ophthalmology & Eye Science, 0, , 34-38.	1.5	0
1322	Approved pharmacotherapy for macular edema secondary to branch retinal vein occlusion: A review of randomized controlled trials in dexamethasone implants, ranibizumab, and aflibercept. World Journal of Ophthalmology, 2015, 5, 106.	0.1	0
1323	The Controversies Surrounding Bevacizumab and Ranibizumab. Advances in Research, 2015, 3, 334-340.	0.3	0
1324	Intravitreal Steroids for the Treatment of Macular Edema in Retinal Vein Occlusions. , 2015, , 69-79.		0

#	Article	IF	Citations
1325	Experience of intravitreal injections in a tertiary Hospital in Oman. Oman Journal of Ophthalmology, 2015, 8, 166.	0.2	1
1326	Terapias Presentes y Futuras para tratar Degeneración Macular Relacionada con la Edad. Highlights of Ophthalmology, 2015, 43, 13-17.	0.0	0
1327	Biweekly Bevacizumab for Refractory Neovascular Age-related Macular Degeneration. International Journal of Ophthalmology and Clinical Research, 2015, 2, .	0.1	0
1328	Ophthalmika. , 2016, , 621-641.		0
1329	Neovascular Glaucoma. Essentials in Ophthalmology, 2016, , 149-157.	0.0	0
1330	Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digital Journal of Ophthalmology: DJO, 2015, 21, 29-34.	0.2	7
1331	Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting. International Journal of Ophthalmology, 2016, 9, 424-30.	0.5	0
1332	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. International Journal of Particle Therapy, 2016, 2, 555-569.	0.9	0
1333	6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome. International Journal of Ophthalmology, 2016, 9, 551-5.	0.5	1
1334	Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 458-465.	0.4	3
1335	Paradigm of Susceptibility Genes in AMD and PCV. Essentials in Ophthalmology, 2017, , 169-192.	0.0	1
1336	Ophthalmika. , 2017, , 641-661.		0
1337	Scharioth Macula Lens. , 2017, , 105-108.		0
1338	Automatic versus Manual Segmentation of Choroidal Neovascularization Lesions Using Optical Coherence Tomography. Advances in Ophthalmology & Visual System, 2017, 6, .	0.2	0
1339	Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab. International Journal of Ophthalmology, 2017, 10, 423-426.	0.5	3
1340	Two-year Outcomes after Intravitreal Anti-vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy Patients with Good Initial Visual Acuity. Journal of Retina, 2017, 2, 12-20.	0.1	0
1341	Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis. International Journal of Ophthalmology, 2017, 10, 1280-1289.	0.5	6
1342	Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia. International Journal of Ophthalmology, 2017, 10, 1889-1897.	0.5	3

#	Article	IF	Citations
1344	Ophthalmika. , 2018, , 693-714.		0
1345	Correlates of Good Vision in Eyes With Subfoveal Scars From Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 765-774.	0.4	0
1347	Bevacizumab for eye diseases â€“ Legal, regulatory, and ethical overview. Indian Journal of Pharmacology, 2019, 51, 377.	0.4	6
1348	Ophthalmika. , 2019, , 877-902.		0
1349	Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 4317-4326.	0.9	15
1350	Intravenous route to choroidal neovascularization by macrophage-disguised nanocarriers for mTOR modulation. Acta Pharmaceutica Sinica B, 2022, 12, 2506-2521.	5.7	19
1351	Ophthalmika. , 2020, , 733-758.		0
1352	Health Promotion, Audit, Research and Evidence-Based Medicine. , 2020, , 189-220.		0
1353	TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. BMJ Open Ophthalmology, 2020, 5, e000588.	0.8	0
1354	Two different treatment regimens of ranibizumab 0.5Âmg for neovascular ageâ€related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. Acta Ophthalmologica, 2021, 99, e336-e345.	0.6	3
1357	Clinical Trials Related to Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. , 2020, , 259-281.		1
1358	Disorders of the Macula. , 2020, , 41-48.		0
1359	Retinal OCT Analysis and Prediction with Deep Learning. , 2020, , .		0
1360	Home Monitoring for Age-Related Macular Degeneration. , 2020, , 363-373.		2
1361	IntroductionÂand Basic Concepts in Stem Cell Research and Therapy: The Facts and the Hype. Learning Materials in Biosciences, 2020, , 1-36.	0.2	0
1362	Macular Atrophy Affecting Visual Outcomes in Patients Undergoing Anti-VEGF Treatment in Routine Clinical Practice. Ophthalmic Surgery Lasers and Imaging Retina, 2020, 51, 68-75.	0.4	2
1363	Side Effects of Brolucizumab. Journal of Ophthalmic and Vision Research, 2021, 16, 670-675.	0.7	6
1364	Reticular pseudodrusen: A critical phenotype in age-related macular degeneration. Progress in Retinal and Eye Research, 2022, 88, 101017.	7.3	56

#	Article	IF	Citations
1366	Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2020, 15, 331-340.	0.7	5
1367	CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS. Retina, 2021, 41, 1242-1250.	1.0	5
1368	Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. International Journal of Ophthalmology, 2012, 5, 759-70.	0.5	5
1369	Vitamins for age-related macular degeneration demonstrate minimal differences. Canadian Family Physician, 2013, 59, 503.	0.1	2
1370	Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2013, 111, 56-69.	1.4	10
1371	Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration. International Journal of Ophthalmology, 2013, 6, 600-5.	0.5	7
1372	Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. International Journal of Ophthalmology, 2014, 7, 355-64.	0.5	18
1373	Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients. Molecular Vision, 2014, 20, 1680-94.	1.1	24
1374	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2014, 112, 160-98.	1.4	20
1375	Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis. International Journal of Ophthalmology, 2015, 8, 138-47.	0.5	6
1376	When important steps for a reliable meta-analysis are missing: the bevacizumab versus ranibizumab case. International Journal of Ophthalmology, 2015, 8, 204-5.	0.5	0
1377	Clinical use of Bevacizumab in treating refractory glaucoma. Journal of Medicine and Life, 2015, 8, 8-12.	0.4	5
1378	Medicare reimbursement to ophthalmologists: a comparison of Hawai'i to other states. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2015, 74, 169-73.	0.4	0
1379	Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 2014, 14, 1-64.	3.0	8
1380	Age-related macular degeneration: anti-vascular endothelial growth factor treatment. Clinical Evidence, 2016, 2016, .	0.2	6
1381	Anti-vascular endothelial growth factor indications in ocular disease. Romanian Journal of Ophthalmology, 2015, 59, 235-242.	0.4	19
1382	Oral Doxycycline Reduces the Total Number of Intraocular Bevacizumab Injections Needed to Control Neovascular Age-related Macular Degeneration. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2017, 6, 23-29.	0.4	2
1383	Use of Fundus Autofluorescence Combined with Optical Coherence Tomography for Diagnose of Geographic Atrophy in Age-Related Macular Degeneration. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2019, 8, 298-305.	0.4	2

#	Article	IF	Citations
1384	The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration. Romanian Journal of Ophthalmology, 2019, 63, 238-244.	0.4	2
1385	Patient Satisfaction of Intravitreal Bevacizumab Injection Services at a Referral Center. Journal of Current Ophthalmology, 2021, 33, 41-47.	0.3	1
1386	TENAYA and LUCERNE. Ophthalmology Science, 2021, 1, 100076.	1.0	24
1387	Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society. Asia-Pacific Journal of Ophthalmology, 2021, 10, 507-518.	1.3	19
1388	Resultados de vida real en el tratamiento de la degeneraciÃ³n macular asociada a la edad neovascular con terapia anti-VEGF. AnÃ¡lisis de 122 pacientes de un solo centro. Archivos De La Sociedad Espanola De Oftalmologia, 2021, , .	0.1	0
1389	Prescribing of lowâ€•versus <scp>highâ€•cost</scp> Part B drugs in Medicare Advantage and traditional Medicare. Health Services Research, 2022, 57, 537-547.	1.0	8
1390	Dexamethasone implant improves anatomic response to anti-VEGF therapy in treatment-resistant polypoidal choroidal vasculopathy. International Ophthalmology, 2022, 42, 1263-1272.	0.6	3
1391	Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: A 42-month retrospective real-world study. Nigerian Journal of Clinical Practice, 2021, 24, 1824.	0.2	0
1392	Ophthalmika. , 2021, , 639-666.		0
1393	USO OFF LABEL DO BEVACIZUMAB. Ensaios USF, 2020, 4, 12-24.	0.1	0
1394	When to believe a subgroup analysis: revisiting the 11 criteria. Eye, 2022, 36, 2075-2077.	1.1	5
1395	To investigate treat and extend versus pro re nata regimen in neovascular age-related macular degeneration: results from the IDEM study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, , 1.	1.0	0
1396	What about the fellow eye in treatment of neovascular ageâ€•related macular degeneration? Analysis of data from the Swedish macula register. Acta Ophthalmologica, 2022, , .	0.6	4
1397	Treatment of macular diseases: an overview of key randomized clinical trials. Rossiiskii Oftal'mologicheskii Zhurnal, 2022, 14, 137-148.	0.1	2
1398	Deep Learning Prediction of Response to Anti-VEGF among Diabetic Macular Edema Patients: Treatment Response Analyzer System (TRAS). Diagnostics, 2022, 12, 312.	1.3	15
1399	Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study. Health Technology Assessment, 2022, 26, 1-142.	1.3	5
1400	Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept. International Journal of Retina and Vitreous, 2022, 8, 11.	0.9	2
1401	Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options. International Journal of Molecular Sciences, 2022, 23, 2592.	1.8	27

#	Article	IF	Citations
1402	Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2022, 33, 131-136.	1.3	7
1403	Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 1834.	1.0	6
1404	The level and efficacy of lutein in patients with age-related macular degeneration: a comprehensive systematic review and meta-analysis. Annals of Translational Medicine, 2022, 10, 299-299.	0.7	3
1405	Reply. Retina, 2022, 42, e20-e22.	1.0	1
1406	Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options. Clinical Ophthalmology, 2022, Volume 16, 917-933.	0.9	29
1407	Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, , 1.	1.0	4
1408	Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, , 1.	1.0	0
1409	The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. Eye, 2022, 36, 1725-1734.	1.1	14
1410	Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology. Molecular Pharmaceutics, 2022, , .	2.3	0
1411	Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology Retina, 2022, 6, 771-785.	1.2	5
1412	Permeability, anti-inflammatory and anti-VEGF profiles of steroidal-loaded cationic nanoemulsions in retinal pigment epithelial cells under oxidative stress. International Journal of Pharmaceutics, 2022, 617, 121615.	2.6	7
1413	Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre. Archivos De La Sociedad Espanola De Oftalmologia, 2021, 97, 191-197.	0.1	0
1414	Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study. Translational Vision Science and Technology, 2021, 10, 27.	1.1	7
1415	Therapy of Pseudoxanthoma Elasticum: Current Knowledge and Future Perspectives. Biomedicines, 2021, 9, 1895.	1.4	11
1416	Retinal Diseases: The Next Frontier in Pharmacodelivery. Pharmaceutics, 2022, 14, 904.	2.0	6
1418	Prevalence and Progression of MacularÂAtrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab. Ophthalmology Retina, 2022, 6, 786-795.	1.2	1
1419	Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis. Journal of Immunology Research, 2022, 2022, 1-11.	0.9	3
1426	Pharmacotherapy of Age-Related Macular Degeneration. , 2022, , 3619-3644.		1

#	Article	IF	Citations
1427	Biomarkers as Predictive Factors of Anti-VEGF Response. Biomedicines, 2022, 10, 1003.	1.4	12
1428	An Off-Label Application of Anti-VEGF in Refractory Posttraumatic Irvine-Gass Syndrome: A Case Report. Klinische Monatsblatter Fur Augenheilkunde, 2022, 239, 534-536.	0.3	1
1429	Delayed follow-up in patients with neovascular age-related macular degeneration treated under universal health coverage: risk factors and visual outcomes. Retina, 2022, Publish Ahead of Print, .	1.0	3
1430	Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Advanced Drug Delivery Reviews, 2022, 187, 114342.	6.6	29
1431	The Role of Retinal Plasticity in the Formation of Irreversible Retinal Deformations in Age-Related Macular Degeneration. Current Eye Research, 2022, , 1-7.	0.7	0
1432	A novel, minimally invasive implant to assist in repeated intraocular drug delivery. Biomedical Microdevices, 2022, 24, 17.	1.4	0
1433	The negative impact of COVID-19 pandemic on age-related macular degeneration patients treated with intravitreal bevacizumab injections. International Ophthalmology, 2022, 42, 3387-3395.	0.6	3
1434	OCT-Derived Radiomic Features Predict Antiâ€“VEGF Response and Durability in Neovascular Age-Related Macular Degeneration. Ophthalmology Science, 2022, 2, 100171.	1.0	5
1435	Correlation between the progression of diabetic retinopathy and inflammasome biomarkers in vitreous and serum â€“ a systematic review. BMC Ophthalmology, 2022, 22, .	0.6	12
1436	Effect of Alcohol on Vascular Endothelial Growth Factor Expression in Retinal Pigment Epithelium Cells and Angiogenesis. Journal of Retina, 2022, 7, 1-8.	0.1	0
1437	Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. International Ophthalmology Clinics, 2022, 62, 35-47.	0.3	1
1438	Evaluation of a self-imaging SD-OCT system designed for remote home monitoring. BMC Ophthalmology, 2022, 22, .	0.6	21
1439	Impact of Persistent Retinal Fluid in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice. Ophthalmic Surgery Lasers and Imaging Retina, 2022, 53, 317-324.	0.4	0
1440	A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration. Frontiers in Medicine, 0, 9, .	1.2	2
1441	Emotional and physical experiences of people with neovascular age-related macular degeneration during the injection process in Germany: a qualitative study. BMJ Open, 2022, 12, e058266.	0.8	4
1442	Characterizing early residual fluid in neovascular age-related macular degeneration using machine learning in routine clinical practice. Ophthalmology Retina, 2022, , .	1.2	0
1443	Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration. Ophthalmology and Therapy, 2022, 11, 1705-1717.	1.0	9
1444	Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting. International Ophthalmology, 0, , .	0.6	1

#	Article	IF	Citations
1445	The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study. PLoS ONE, 2022, 17, e0271999.	1.1	2
1446	Recent Advances in Age-Related Macular Degeneration Therapies. Molecules, 2022, 27, 5089.	1.7	23
1447	A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The â€œELEVATEâ€•Study. Clinical Ophthalmology, 0, Volume 16, 2579-2593.	0.9	1
1448	Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261, 345-352.	1.0	5
1449	The Immunohistochemical Assessment of Neoangiogenesis Factors in Squamous Cell Carcinomas and Their Precursors in the Skin. Journal of Clinical Medicine, 2022, 11, 4494.	1.0	5
1450	Characteristics of choroidal neovascularization in elderly eyes with high myopia not meeting the pathologic myopia definition. Scientific Reports, 2022, 12, .	1.6	2
1451	Automatic quantification of retinal photoreceptor integrity to predict persistent disease activity in neovascular age-related macular degeneration using deep learning. Frontiers in Neuroscience, 0, 16, .	1.4	4
1452	Predicting treat-and-extend outcomes and treatment intervals in neovascular age-related macular degeneration from retinal optical coherence tomography using artificial intelligence. Frontiers in Medicine, 0, 9, .	1.2	4
1453	Investigational drugs in clinical trials for macular degeneration. Expert Opinion on Investigational Drugs, 2022, 31, 1067-1085.	1.9	12
1454	Analysis of the sustained release ability of bevacizumab-loaded tetra-PEG gel. Experimental Eye Research, 2022, 223, 109206.	1.2	3
1455	The aging eye and age-related ocular pathologies. , 2023, , 319-338.		0
1456	Age-related macular degeneration and its treatment options. , 2022, , 333-342.		0
1457	Intravitreal Aflibercept Application in Patients with Type 1 Choroidal Neovascular Membrane Resistant to Ranibizumab Treatment Results. Medical Journal of Western Black Sea, 2022, 6, 150-157.	0.2	0
1458	Non-neovascular fluid in age-related macular degeneration: observe-and-extend regimen in a case-series study. Canadian Journal of Ophthalmology, 2022, , .	0.4	2
1459	The Impact of Early Residual Fluid After Anti-Vascular Endothelial Growth Factor Initiation in Patients With Neovascular Age-Related Macular Degeneration: A Meta-Analysis Review. Ophthalmic Surgery Lasers and Imaging Retina, 2022, 53, 506-513.	0.4	1
1460	Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration. Eye, 2023, 37, 1844-1849.	1.1	2
1461	Treat & extend in neovascular age-related macular degeneration: how we got here and where do we go next?. Eye, 0, , .	1.1	0
1462	Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal antibody, for the treatment of wet age-related macular degeneration. International Journal of Ophthalmology, 2022, 15, 1549-1553.	0.5	2

#	Article	IF	Citations
1463	DegeneraÃ§Ã£o macular relacionada Ã idade e ao sistema purinÃ©rgico. , 2021, , 362-373.		0
1464	Pars plana vitrectomy and subretinal tissue plasminogen activator for large exudative submacular hemorrhage: a case series. BMC Ophthalmology, 2022, 22, .	0.6	2
1465	Evaluation of an Artificial Intelligence-Based Detector of Sub- and Intraretinal Fluid on a Large Set of Optical Coherence Tomography Volumes in Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmologica, 2022, 245, 516-527.	1.0	10
1466	Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2022, 53, 546-552.	0.4	0
1467	Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment. Oftalmologiya, 2022, 19, 647-657.	0.2	0
1468	RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS. Retina, 2022, 42, 2134-2142.	1.0	13
1469	Age related macular degeneration â€“ a review. The Optician, 2016, 2016, 123-1.	0.0	0
1470	Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration. Biomolecules, 2022, 12, 1629.	1.8	20
1471	The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD. Diagnostics, 2022, 12, 2807.	1.3	1
1472	Immunogenicity: Clouding the Future of Intravitreal Therapy. Ocular Immunology and Inflammation, 2023, 31, 1746-1749.	1.0	1
1473	Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2023, 7, 300-306.	1.2	3
1474	Effect of Ranibizumab and Aflibercept on Retinal Pigment Epithelial Detachment, Subretinal, and Intra-Retinal Fluid in Age-Related Macular Degeneration. Ceska A Slovenska Oftalmologie, 2022, 78, 176-185.	0.1	0
1475	Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons. Clinical Ophthalmology, 0, Volume 16, 4273-4279.	0.9	6
1476	Electrophysiological Evaluation of Macular Photoreceptor Functions in Patients with Choroidal Neovascular Membranes. Current Eye Research, 0, , 1-7.	0.7	0
1477	Comparison of Snellen Visual Acuity Measurements in Retinal Clinical Practice to Electronic ETDRS Protocol Visual Acuity Assessment. Ophthalmology, 2023, 130, 533-541.	2.5	6
1478	A Novel â€œInsideâ€Outâ€•Intraocular Nanomedicine Delivery Mode for Nanomaterialsâ€™ Biological Effect Enhanced Choroidal Neovascularization Occlusion and Microenvironment Regulation. Advanced Materials, 2023, 35, .	11.1	12
1479	Cost impact of different treatment regimens of brolucizumab in neovascular age-related macular degeneration: A budget impact analysis. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 1350-1364.	0.5	0
1480	Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. Eye, 2023, 37, 2438-2453.	1.1	10

#	Article	IF	Citations
1481	Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 0, Volume 16, 4041-4046.	0.9	11
1482	Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy. BMC Ophthalmology, 2022, 22, .	0.6	3
1483	Evaluation of Multiple Machine Learning Models for Predicting Number of Anti-VEGF Injections in the Comparison of AMD Treatment Trials (CATT). Translational Vision Science and Technology, 2023, 12, 18.	1.1	4
1484	Treatment of neovascular age-related macular degeneration: insights into drug-switch real-world from the Berlin Macular Registry. Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261, 1681-1690.	1.0	1
1485	SkQ1 as a Tool for Controlling Accelerated Senescence Program: Experiments with OXYS Rats. Biochemistry (Moscow), 2022, 87, 1552-1562.	0.7	7
1486	Investigation of incidence and causes of acute vision loss during anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration during a 4-year follow-up. Retina, 2023, Publish Ahead of Print, .	1.0	0
1487	Associations between Serial Intravitreal Injections and Dry Eye. Ophthalmology, 2023, 130, 509-515.	2.5	7
1488	INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM. Retina, 2023, 43, 506-513.	1.0	0
1489	Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection. Journal of Ocular Pharmacology and Therapeutics, 2023, 39, 215-224.	0.6	0
1490	Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection. American Journal of Ophthalmology Case Reports, 2023, 30, 101829.	0.4	0
1491	STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2023, 43, 420-432.	1.0	2
1492	Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18Âmonths in real-world eyes with neovascular age-related macular degeneration. International Journal of Retina and Vitreous, 2023, 9, .	0.9	6
1493	Augenerkrankungen. , 2022, , 569-598.		0
1494	VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?. Hypertension, 2023, 80, 901-911.	1.3	4
1495	Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy. International Journal of Molecular Sciences, 2023, 24, 3876.	1.8	5
1496	Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology Retina, 2023, 7, 564-572.	1.2	2
1497	Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. Journal of Translational Medicine, 2023, 21, .	1.8	10
1498	Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center. Ophthalmologica, 2023, 246, 58-67.	1.0	2

#	Article	IF	Citations
1499	Morphological Macular Changes Under Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration Refractory to Previous Anti-VEGF Treatment Compared with Treatment-Naive Eyes. Clinical Ophthalmology, 0, Volume 17, 769-777.	0.9	0
1500	Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmic Surgery Lasers and Imaging Retina, 2023, 54, 223-230.	0.4	0
1501	SEVERE VISUAL LOSS DURING ANTI-VEGF INTRAVITREAL INJECTIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: TIMING, PROGNOSIS, AND OPTICAL COHERENCE TOMOGRAPHY FINDINGS. Retina, 2023, 43, 1081-1087.	1.0	2
1502	Pseudophakia as a surprising protective factor in neovascular age-related macular degeneration. Journal Francais D'Ophtalmologie, 2023, , .	0.2	1
1503	Common retinal disorders. , 2018, , 413-435.		0
1504	Pathways of Fluid Leakage in Age-Related Macular Degeneration. Retina, 2023, 43, 873-881.	1.0	8
1505	Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems. Pharmaceutics, 2023, 15, 1094.	2.0	8
1506	Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2023, 7, 661-671.	1.2	5
1514	Case Report: Successful treatment of external beam radiation-induced optic papillopathy with intravitreal anti-VEGF. Frontiers in Ophthalmology, 0, 3, .	0.2	0
1519	Systematic Review of Neovascular Age-Related Macular Degeneration Disease Activity Criteria Use to Shorten, Maintain or Extend Treatment Intervals with Anti-VEGF in Clinical Trials: Implications for Clinical Practice. Ophthalmology and Therapy, 0, , .	1.0	1
1524	Nanotechnological strategies for the treatment of diabetic retinopathy. , 2023, , 285-304.		0